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1.1 English Summary 
Background 
Shoulder adhesive capsulitis, also called frozen shoulder, is a painful chronic 
condition causing reduced movement at the gleno-humeral joint in several planes 
affecting shoulder function. Shoulder adhesive capsulitis can be a challenge in both 
diagnosis and management. As range of motion is an important criterion in follow-up 
of these patients, high intertester reliability for measurement of range of motion is 
essential in an environment where a fellow colleague may follow the patient further. 
There is a need for an evidence-based easy and pragmatic treatment approach for this 
condition in general practice. Intraarticular corticosteroid injections by posterior 
approach using landmarks is an important treatment modality for this condition in 
primary care that needs to be explored further. Awareness of that comorbidity may 
affect outcome in musculoskeletal conditions is important to keep in mind. 
 
Objectives 
1. To examine intertester reliability of measuring passive range of motion (PROM) 
bilaterally using plurimeter in patients with adhesive shoulder capsulitis over an 
8-weeks period and examine whether the measurement error remained the same. 
2. Investigate the effect, if any, of multiple corticosteroid injections with distension 
as compared to corticosteroid injections alone and to treatment-as-usual. 
3. Determine whether treatment outcome can be predicted by subjective health 
complaints and neuroticism in patients with frozen shoulder as measured by 








The first study is a prospective intertester reliability study for measurement of PROM 
in the shoulder of 50 patients with frozen shoulder. Two testers measured PROM 
with a plurimeter several times during an 8-week period. The second study is a 
randomised controlled single blinded three-armed trial comparing effect of two 
different interventions with treatment-as-usual in 106 patients. Treatment-as-usual in 
this scenario means any other conservative treatment like non-steroid anti-
inflammatory drugs, painkillers, physiotherapy and acupuncture but no steroids to be 
used orally or as injection. The intervention consisted of four intraarticular steroid 
injections with or without distension. SPADI was the primary outcome measure, 
Numerical Pain Rating Scale (NPRS) secondary, and PROM, the tertiary outcome 
measure. The third study is observational where we investigated whether comorbid 
factors measured with the questionnaires Subjective Health Complaints (SHC) and 
Neuroticism can predict outcome of the given treatment in 105 patients. We collected 
data from patients answering the questionnaires at baseline and at the end of 8-week 
clinical follow up. 
 
Results 
Study I: Intertester agreements varied from very good to excellent for PROM for all 
three time-points for the affected arm. Very reliable to excellent values were achieved 
for intraclass correlation coefficient (ICC 2.1). The measurement error remained the 
same throughout.  
Study II: At short-term (4 and 8 weeks) statistically significant differences (p<0.01) 
in change scores for SPADI, NPRS and PROM were observed when comparing those 
receiving corticosteroid injections, with or without distension, to treatment-as-usual. 
At long-term (12 months) there was no difference between the three groups for 
SPADI (p>0.05). A large effect size (ES) was observed between both injection 
groups and treatment-as-usual (ES 1.2) at short term. The effect size between the 
injection groups and treatment-as-usual was reduced to low (ES 0.3 and 0.4) at 12 




weeks) or long-term (12 months) was not statistically significant. All participants 
recovered. 
Study III: Little comorbidity was observed in the 105 patients included in the study, 
as measured with the questionnaire Subjective Health Complaints (SHC). Significant 
predictive power (p<0.001) was exhibited by the Pseudoneurology subscale in SHC 




Study I: Intertester reliability between the two testers over a time-period of 8 weeks 
measuring PROM in patients with adhesive shoulder capsulitis with a plurimeter was 
very good. This method can reliably determine passive range of motion in this patient 
population and be a reliable outcome measure. 
Study II: This randomised controlled trial indicated that four serial injections with 
corticosteroid with or without distension during 8 weeks were better than treatment-
as-usual in treatment of patients with adhesive shoulder capsulitis. However, no 
difference was found between any of the groups at 12 months, indicating that natural 
healing takes place independent of treatment. 
Study III: Comorbidity as measured by the Pseudoneurology subscale in the SHC 
questionnaire did predict the treatment outcome in frozen shoulder as measured by 
SPADI at 8 weeks, whereas when measured by change in SPADI from baseline to 8 







1.2 Norwegian summary – norsk sammendrag 
Bakgrunn 
Skulder kapsulitt, også kalt frossen skulder, er en smertefull tilstand som forårsaker 
redusert bevegelighet i flere plan og påvirker skulder-funksjon. Skulder kapsulitt kan 
være en utfordring både diagnostisk og behandlingsmessig. Korrekt måling av 
passive bevegelser er derfor viktig i oppfølging av pasienter der terapeuter ofte må 
følge opp andres pasienter med frossen skulder. Det er behov for evidensbaserte 
pragmatiske løsninger for behandling av frossen skulder i allmennpraksis. 
Intraartikulære steroid injeksjoner etter landemerker med bakre tilgang er en 
pragmatisk konservativ behandlingsmetode for frossen skulder i allmennpraksis. En 




1. Undersøke intertester reliabilitet for måling av passive bevegelsesutslag 
(PROM) bilateralt med plurimeter hos pasienter med frossen skulder over en 8 
ukers periode, samt undersøke om målefeil forblir uendret. 
2. Undersøke om en serie med fire steroid-injeksjoner med eller uten distensjon 
påvirker forløp av frossen skulder sammenlignet med vanlig brukt konservativ 
behandling uten steroid.  
3. Utforske om subjektive helseplager og nevrotisisme kan forutsi utfall av 




Første studie er en prospektiv intertester reliabilitetsstudie for måling av PROM på 
skulder hos 50 pasienter med frossen skulder. To testere målte PROM med plurimeter 
flere ganger i løpet av 8 uker. I den andre studien som er en randomisert kontrollert 




injeksjoner uten distensjon og med distensjon, mot vanlig brukt konservativ 
behandling (kontrollgruppen) som for eksempel ikke-steroid betennelsesdempende 
midler, smertestillende, fysioterapi og akupunktur. Deltakerne i 
intervensjonsgruppene fikk fire intraartikulær steroid injeksjoner med og uten 
distensjon over en 8 ukers periode. SPADI ble brukt som primært utfallsmål, 
numerisk smerteskala (Numerical Pain Rating Scale (NPRS) sekundært og PROM 
som tertiært utfallsmål.  
Den tredje studien er en observasjonsstudiet av 105 deltakere der vi undersøkte om 
subjektive helseplager og nevrotisisme kan forutsi utfall av gitt behandling. 
Pasientene besvarte spørreskjemaene ved start og etter 8 uker.  
 
Resultater 
Studie I: Samsvar ved måling av PROM i affisert skulder ved test-tidspunktene var 
enten veldig god eller utmerket. Fra veldig pålitelig til utmerkete verdier ble registrert 
for intraklasse korrelasjonskoeffisient (ICC 2.1) og målefeilen var den samme i 
testperioden. 
Studie II: På kort sikt (4 og 8 uker) ble det påvist statistisk signifikant forskjell 
(p<0.01) for endring i SPADI, for NPRS og PROM når steroid injeksjoner uten eller 
med distensjon ble sammenlignet med vanlig konservativ behandling (kontroll- 
gruppen). Det var ingen forskjell mellom de tre gruppene på lang sikt (12 måneder) 
for SPADI (p>0.05). 
Det ble registrert stor effekt-størrelse (ES) på kort sikt mellom injeksjonsgruppene og 
gruppen som fikk vanlig konservativ behandling (kontrollgruppen). Denne effekt-
størrelsen mellom injeksjonsgruppene og kontrollgruppen ble lav (ES 0,3 og 0,4) på 
lang sikt (12 måneder). Det var ingen statistisk signifikant forskjell mellom 
injeksjonsgruppene hverken på kort sikt (4 og 8 uker) eller på lang sikt (12 måneder). 
Alle ble like bra til slutt. 
Studie III: Det ble funnet lite komorbiditet hos de 105 pasientene i denne studien, 
målt med spørreskjema vedrørende Subjektive helseplager (SHC). Signifikant 
prediktiv verdi (p<0.001) ble demonstrert kun ved Pseudonevrologi subskalaen i SHC 






Studie I: Svært god intertester reliabilitet mellom de to testerne over en periode på 8 
uker ble registrert ved måling av passive bevegelsesutslag med plurimeter hos 
pasienter med frossen skulder. Denne målemetoden kan brukes som et pålitelig 
utfallsmål av passive bevegelsesutslag.  
Studie II: Denne randomiserte kontrollerte studien på pasienter med frossen skulder 
indikerer at fire intraartikulære steroid injeksjoner i serie med eller uten distensjon 
var bedre enn vanlig konservativ behandling i en periode på 8 uker. Ingen forskjell 
ble funnet mellom gruppene ved 12 måneder, noe som tyder på naturlig tilheling, 
uavhengig av gitt behandling. 
Studie III: Komorbiditet målt med subskalaen Pseudonevrologi i spørreskjemaet 
SHC predikerte behandlingsutfall i frossen skulder målt med SPADI ved 8 uker, men 
ikke når målt i forhold til endring i SPADI fra utgangspunktet til 8 uker. 
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2. Introduction - background 
Shoulder adhesive capsulitis, also called frozen shoulder, is a painful chronic 
condition causing reduced movement at the gleno-humeral joint in several planes. 
Apparently, restricted active movements have been confused with characteristically 
painful restricted active and passive movements in frozen shoulder, leading to over 
diagnosis. A need for standardisation of diagnostic definition has been emphasised (1, 
2). The condition was first described by Dupley in 1896, later termed as “frozen 
shoulder” by Codman in 1934 and described as “difficult to define, difficult to treat 
and difficult to explain” (3) and as “adhesive capsulitis” by Neviaser in 1945 (4). 
Some authors suggest abandoning the term adhesive capsulitis as adhesions are not 
seen on arthroscopy in patients with frozen shoulder, but instead synovitis, thickening 
and contracture of the gleno-humeral joint capsule can be seen (5-8). “The surgical 
findings showed a consistent alteration in the rotator interval and coracohumeral 
ligament. The rotator interval was obliterated, and the coracohumeral ligament was 
transformed into a tough contracted band” (9). Bunker suggested the term contracture 
of the shoulder (10), which was further modified to be called frozen shoulder 
contracture syndrome (11). In this thesis, the terms ‘frozen shoulder’, “shoulder 
capsulitis” and ‘adhesive shoulder capsulitis’ will be used interchangeably. 
 
Frozen shoulder may be primary or secondary, a term introduced by Lundberg (12). 
Primary refers to cases without any apparent cause, while secondary is often 
associated with trauma or other systemic conditions such as diabetes, thyroid disease, 
cardiovascular disease and hemiparesis, among which diabetes is the largest group 
with a severe and protracted disease course (6, 13-15). Others have suggested further 
division of secondary frozen shoulder into three subcategories: intrinsic, extrinsic and 
systemic types (2). Intrinsic type occurs in association with rotator cuff disorders 
(tendonitis and partial or full thickness tears), biceps tendonitis or calcific tendonitis 
with calcific deposits within the subacromial space/rotator cuff tendons). In extrinsic 




previous ipsilateral breast surgery, cervical radiculopathy, chest wall tumor, previous 
cerebrovascular accident or more local extrinsic disorders such as previous humeral 
shaft fractures, acromioclavicular arthritis or clavicle fractures. The systemic types 
occur in association with systemic disorders such as diabetes mellitus, hypo- and 
hyperthyroidism and heart disease, but the association may not be definite. 
 
2.1 Epidemiology 
Frozen shoulder affects 2-5% of the general population (15-17) and about 11-14% of 
diabetic patients (16, 18). Frozen shoulder affects mostly middle-aged persons (6, 19, 
20) and women in their fifties are commonly affected (16, 17). Both shoulders may be 
affected simultaneously or one of the shoulders may be affected later (16, 17, 21-23). 
Genetic factors may play a role in the aetiology of frozen shoulder (24). A strong 
association between shoulder capsulitis and Dupuytren’s disease attributed to genetic 
factors has been shown by earlier studies (6, 7, 25, 26). Frozen shoulder may affect 
activities of daily living causing dysfunction in the aged population and may lead to 
increased sick leave in the working population (27). 
 
2.2 Pathoanatomy, pathophysiology and histopathology 
The pathogenesis of frozen shoulder is not well understood and various theories have 
been put forward. Most commonly, there is synovitis and contracture of capsule 
leading to restriction of movements in primary frozen shoulders. Contracture of the 
antero-superior capsule, antero-inferior capsule and postero-superior capsule leads to 
most restriction of lateral rotation in adduction, lateral rotation in abduction and 
medial rotation respectively (1). Structures commonly involved are gleno-humeral 
ligament, coraco-humeral ligament and joint capsule in the rotator interval, also 




Synovial tissue between the long head of biceps and the rotator interval has shown 
vascular proliferation with fibrin and fibrous tissue in frozen shoulders (31). 
Histologically there is presence of both chronic inflammatory cell infiltrate and 
fibrosis in biopsies during capsulotomy (32). These findings are similar in 
Dupuytren’s contracture with a mature type III collagen containing fibroblasts and 
myofibroblasts (7). It is suggested that cytokines and growth factors induce 
production of fibroblasts, which leads to production of type III collagen. Cytokines 
may also stimulate angiogenesis giving the new blood vessel appearance on the 
capsular surface on arthroscopy. Capsular tissue has been found to contain increased 
mRNA for metalloproteinases, which can degrade the connective tissue matrix, and 
metalloproteinase inhibitor (33). Biopsies of capsules from adhesive capsulitis 
shoulders have revealed cytokines. These are transforming growth factor-β and 
platelet-derived growth factor that may be involved in the inflammatory and fibrotic 
processes in adhesive capsulitis. Matrix-bound transforming growth factor-β may act 
as a persistent stimulus, resulting in capsular fibrosis (34). Reduction of bone mineral 
density in primary frozen shoulder and similarity to Sudeck’s syndrome has led to the 
assumption that it is an algoneurodystrophic process (35). The pain may be 
neurogenic and since the suprascapular nerve contains high proportion of sympathetic 
fibres supplying the joint, suprascapular nerve block can be used (36). 
 
2.3 Natural course 
Clinically, frozen shoulder may be divided into three phases (23): I) Painful phase 
lasting 2-9 months, pain predominant phase with increasing stiffness, II) Stiffening, 
freezing or predominant stiffening phase, lasting 4-12 months, where there is gradual 
reduction of pain but considerable restriction in range of motion (ROM), and III) 
Resolution or thawing phase, lasting 12-42 months with gradual improvement in 
ROM. Others have divided frozen shoulder into four stages relating to the results of 
arthroscopy and physical examination (37). The stiffness stage is usually related to 




supposed (an average total of 30 months, in contrast to about 18 months as often 
postulated). Generally, a longer stiffness stage leads to a longer recovery stage (23). 
Despite the fact that frozen shoulder has been recognised for over 100 years there still 
remains a lack of reliable evidence on the natural and variable history of the condition 
(14). Codman and others have stated that frozen shoulder is a benign condition 
recovering within two years (3, 23, 38, 39), but this may not be true. In a long-term 
follow up study, 50% of patients still had pain after seven years while 60% had 
persistent stiffness (21). Nearly 50% will have a normal shoulder in the long term, 
while 35% will have persistent mild pain and some stiffness in the long term and only 
6% will have severe symptoms (17). Another study estimated 7% to 15% of the 
patients to have some degree of ROM loss which patients were not aware of, while a 
few had functional disability (40). A Finnish study with 2-27 years follow-up showed 
that 94% of the idiopathic shoulders recovered to normal levels of function without 
treatment (41). The outcome differences may be a result of heterogeneous outcome 
measures.  
2.4 Diagnosis 
Frozen shoulder is essentially a clinical diagnosis based on the findings of passive 
range of motion (8, 42). ROM is often used as an outcome measure to demonstrate 
effect of the interventions in frozen shoulder (43-45). To ascertain the diagnosis, 
reliable ROM measurement, irrespective of the measuring instrument, is important. 
However, no consensus exists as to degree of restriction required in range of motion 
to diagnose frozen shoulder, leading to confusion in clinical diagnosis. Frozen 
shoulder remains mainly a clinical diagnosis for lack of other formal diagnostic 
criteria (46). Other authors include in diagnostic criteria exclusion of other 
pathologies like osteoarthritis of the gleno-humeral joint, dislocation and sarcomas 
and a normal radiograph (1, 11). Radiographs in frozen shoulder may depict 
significant loss of bone mineral density, but has good prognosis in the long term (47). 




Generally, there is a marked loss of external rotation with the arm in both neutral and 
abduction, which may not reach 90 degrees (1). Cyriax used the term “capsular 
pattern” to emphasize that in frozen shoulder passive external rotation is most limited 
and passive internal rotation least, while reduction of passive abduction is somewhere 
in between (48) (page 33). This is generally true, but there may be exceptions, as in 
some patients, passive internal rotation may be more restricted than external rotation.  
 
MRI can show synovial and capsular thickening in frozen shoulder (49). Thickening 
of coracohumeral ligament and capsule in rotator interval is a characteristic finding in 
MRI arthrography in frozen shoulder (29). MRI is not imperative for diagnosis and 
may result in false negatives. 
 
Considering differential diagnosis, associated conditions like calcified tendinopathies, 
fractures of greater tuberosity and tears of rotator cuff and early osteoarthritis of the 
glenohumeral joint can be present with frozen shoulder. Red flags are rare, but one 
should bear in mind osteosarcoma and possibility of metastases. Plane radiograph or 
ultrasound examination is sufficient to exclude these pathologies (1, 11). 
 
2.5 Management 
Treatment of frozen shoulder aims to relieve pain and regain function by increasing 
range of motion. There are many types of treatment used to manage the frozen 
shoulder, but there is lack of consensus on best management of this painful condition 
(50). Several conservative treatment strategies are used such as non-steroid anti-
inflammatory drugs, physiotherapy in its various forms, acupuncture, per oral 
prednisolone, intraarticular corticosteroid injection with or without distension, and 
hyaluronic acid injections. Manipulation under anaesthesia and capsulotomy is used 





2.5.1 Non-steroid anti-inflammatory drugs (NSAIDs) 
Use of NSAIDs may relieve pain in frozen shoulder. Three trials in a systematic 
review demonstrated superior short-term efficacy of NSAIDs in comparison with 
placebo intervention for shoulder pain. Fourteen trials comparing two types of 
NSAIDs showed no conclusive evidence in favour of any particular NSAID with 
respect to efficacy or tolerability (43). 
 
2.5.2 Physiotherapy 
Physiotherapy is commonly prescribed in frozen shoulder and passive mobilisation 
and stretching is commonly used. This however, may have negative effects in the 
inflammatory painful phase when analgesic treatment and modified activity in pain-
free range is best suited (1). Efficacy of physiotherapy in frozen shoulder, particularly 
in the painful phase, is debated. According to a Cochrane review: ”Based on 25 
clinically heterogeneous trials, we are uncertain of the effect of manual therapy or 
exercise when not delivered together, as most reported differences between groups 
were not clinically or statistically significant, and the evidence is mostly of low 
quality” (53). Another study did not find any difference in outcome regardless of the 
technique of mobilization used (54). In a prospective study of 77 patients with 
idiopathic frozen shoulder syndrome, effect of intensive physical rehabilitation 
treatment, including passive stretching and manual mobilization (stretching group), 
were compared with supportive therapy and exercises within the pain limits (watchful 
waiting group). Watchful waiting yielded better outcomes than intensive physical 
therapy and passive stretching in patients with frozen shoulder (55). 
 
In a retrospective study, Jewell et al. demonstrated positive effect of mobilization and 
exercise for patients with adhesive capsulitis while ultrasound, massage, 
iontophoresis, and phonophoresis reduced the likelihood of a favourable outcome 




with home exercise, may be beneficial in management of frozen shoulder (57, 58). In 
a prospective outcome study for conservative treatment including physiotherapy and 
passive stretching, positive results were seen in 90% of the patients (59). Better 
results were registered in a 3.8 years follow-up of 110 shoulders by moderate 
mobilization than mobilization under anaesthesia (60). Another study found 
equivalent effect of physiotherapy and corticosteroid injection with cautious 
interpretation of results due to heterogeneity of studies included in the review (61). In 
a review, Struyf et al. have discussed the role of physiotherapy in frozen shoulder and 
state that although some physiotherapeutic interventions show evidence regarding 
reducing pain or increasing mobility, there is little evidence to suggest that the 
disease prognosis is affected. A change in physiotherapy approach to these patients is 
therefore suggested (62). 
 
2.5.3 Oral corticosteroids 
Oral corticosteroids can be helpful in reducing pain in the painful phase of frozen 
shoulder. In a study by Binder et al. 10mg of daily prednisolone improved pain at 
night and patients had a rapid initial recovery, but no difference was registered after 5 
months compared to the control group (63). This finding is supported in a prospective 
double-blind randomised placebo-controlled trial in 50 patients administering 30 mg 
prednisolone for three weeks. Significant reduction in pain and better function was 
revealed in the steroid group at 3 and 6 weeks, but effects were not maintained after 6 
weeks (64). In a systematic Cochrane review, there is evidence of significant short-
term benefits in pain, range of motion and function in adhesive capsulitis, but the 
effect may not be maintained beyond 6 weeks (65). 
 
2.5.4 Intraarticular corticosteroid injection 
Many studies have demonstrated short-term benefit of intraarticular corticosteroid 




meta-analysis concluded, “Intraarticular injection for adhesive capsulitis may be 
beneficial although their effect may be small and not well-maintained” (71). 
Therapists very often combine physiotherapy with intraarticular corticosteroid to 
enhance the treatment effect (66, 69).  
 
It is claimed that injection technique regarding anterior or posterior approach and 
accuracy of placement of needle may play a role while others have a different opinion 
(72). By accuracy of placement we mean that the opening of the needle is between 
cartilage and shoulder capsule. In practice, it means that the physician has to touch 
the bone (humeral head) before starting to inject the solution to be certain that the 
needle end is intraarticular. In anterior approach, patient can be sitting or in half-
lying. The needle, 4 to 5 cm long 21 gauze, is inserted 1-2 cm lateral to the coracoid 
process at 45 degrees (73, 74). The posterior approach by landmarks in this thesis is 
described under Intervention in section 3.6 (72, 74). In a cadaver study, 80% 
accuracy rate was achieved by anterior approach as compared to 50% by posterior 
approach (75). White et al. found better results with anterior approach than posterior 
approach (76). Anatomically correctly placed injection gave better results in two 
studies (77, 78). Corticosteroid injection in rotator interval gave clinical important 
improvement in function measured by Shoulder Pain and Disability Index (SPADI) 
after 12 weeks (79). In another study, no difference was found between intraarticular 
and rotator interval ultrasound guided corticosteroid injection (80). Some suggest 
that ultrasound guided intraarticular corticosteroid injections give better outcome than 
injections given by landmarks (81). In another study, the difference between 
ultrasound-guided intraarticular corticosteroid injection and intraarticular injection by 
landmarks did not last beyond 3 weeks (82). A Cochrane review did not find any 
added benefit by ultrasound-guided corticosteroid injections in shoulder pain (83). 
 
Intraarticular steroid dose has also been compared to assess difference between low 
and high dose. De Jong et al. found better outcome with higher dose comparing 10 
mg to 40 mg Triamcinolone acetonide (84), while another study did not find any 




corticosteroid injections have been on single intraarticular injection and there is a 
debate whether multiple injections are more beneficial than single intraarticular 
injection (26). There are a few studies on multiple intraarticular injections in frozen 
shoulder, but of varying quality and done around 20-30 years ago (17, 67, 84, 86-91). 
A review on multiple intraarticular corticosteroid injections favours multiple 
injections in shoulder capsulitis (26).  
 
2.5.5 Intraarticular corticosteroid injection with distension 
(hydrodilatation) 
Distension by intraarticular normal saline injection without corticosteroid was first 
tried to stretch the capsule. Sixty-four stiff shoulders were treated by injecting 20 ml 
of saline water with contrast in a case series study in 1965 (92). Vad et al. reported 
good results in 19 patients treated by distension and capsular rupture in a non-
randomised controlled trial study (93). In a case series, Betamethasone along with 40 
ml of saline water intraarticular injection by anterior approach to rupture capsule as 
an office procedure was used (94). Good results were reported by hydrodilatation in 
two other studies (95, 96). Since these are case series without randomisation, there is 
a room for bias. Jacobs et al. compared intraarticular steroid injection against capsular 
distension with liquid and air combined and intraarticular steroids and liquid and air 
distension. The difference between the groups was insignificant (87). The volume of 
injected air was small as compared with dilatation with saline of much larger volume 
in other earlier mentioned studies. The distending capacity of the injected air, being 
small in volume, is therefore questionable. In a small randomised controlled trial 
(RCT) comparing intraarticular steroid injection with steroid and distension with 
posterior approach, Gam et al. (90) found larger increase in range of motion as 
compared to intraarticular steroid only. One RCT found better improvement in 
function, pain and range of motion by intraarticular corticosteroid and distension than 
placebo (97). Corbeil et al. did not find any significant difference between distension 




45 patients with shoulder capsulitis (98). Multiple distensions with saline and steroids 
were beneficial up to two distensions, with no added benefit with the third distension 
(99). A Cochrane review found evidence that arthrographic distension with saline and 
steroids provided short-term benefit in pain, range of motion and function (100). 
Another study did not find any significant treatment difference resulting from 
distension with steroids than with intraarticular steroid alone (101). A meta-analysis 
found intraarticular steroid injection as effective as distension in improvement of 
shoulder function and reduction of pain (102). A recent review has concluded that the 
effectiveness of gleno-humeral joint distension was similar to intraarticular 
corticosteroid injection (103) 
 
2.5.6 Manipulation under anaesthesia 
In manipulation under anaesthesia (MUA) a general anaesthetic is administered and 
the shoulder joint capsule is gently stretched by moving the humerus into flexion, 
abduction and then (optionally) moving the adducted shoulder into external rotation 
(104). Good results have been reported for MUA by some studies (105-108). 
However, an RCT did not show any difference between MUA and home exercises 
and the control group who did home exercises in 12 months (109). In another study, 
MUA did not enhance the benefit conferred by home exercises and there is therefore 
need for high-quality research studies (110). Combining corticosteroid injection with 
MUA did not yield any additional benefit (111). Complications can arise under MUA 
and in a post-manipulation arthroscopic study intraarticular lesions as hemarthrosis, 
iatrogenic superior labrum anterior posterior lesions, partial subscapularis tendon 
tears, anterior laberal detachments and tears of the middle glenohumeral ligament 





2.5.7 Arthroscopic capsular release 
Arthroscopic capsular release consists of resecting the contractures in rotator interval, 
releasing coracohumeral ligament, anterio capsule, superior and middle glenohumeral 
ligaments and the subscapular bursa (1). Several studies have reported arthroscopic 
release as an effective and safe treatment for resistant frozen shoulder (113-117). It is 
also considered a cost effective procedure, restoring normal function and health 
related quality of life in most patients with frozen shoulder within 6 months (118). 
Arthroscopic capsular release compared with MUA in a systematic review concluded, 
that available evidence had low quality and that little benefit of capsular release was 
demonstrated instead of or in addition to MUA (119).  
 
2.6 Frozen shoulder, quality of life and comorbidity 
Adhesive capsulitis causes considerable pain and dysfunction, as measured with the 
disease-specific questionnaire SPADI, and quality of life measured with Short Form 
Survey-36 (SF-36) (120). Patients´ own ranking regarding their general health in 
presence of shoulder pain is as high as in some of the medical conditions as heart 
failure, high blood pressure, acute heart infarction, diabetes and depression (121, 
122). The duration and degree of symptoms were found to be prognostic factors for 
recovery from arm, neck and shoulder complaints in a systematic review (123). 
Another review found that longer duration and high degree of shoulder pain level 
partly, contributing to high SPADI scores (124) resulting in chronic shoulder pain 
(125), similar to other findings regarding severity of pain and longer duration causing 
chronification of shoulder pain (126). In patients with full thickness rotator cuff tears, 
patients´ mental health may play an influential role on patient-reported pain and 
function (127). Patients with frozen shoulder experienced worsening of pain and 
dysfunction with comorbidity (15). Improvement in shoulder capsulitis leading to less 




frozen shoulder experienced improved general health as measured by SF-36 after 
arthroscopic capsular release (128, 129).  
 
Health complaints in chronic conditions can be measured by several questionnaires 
(130). The validated questionnaire Subjective Health Complaints (SHC), with 29 
items covering severity and duration of physical and psychological health complaints 
for previous 30 days, is widely used in the Nordic countries. It reliably measures 
health status and comorbidity (131). Subjective health complaints may also cover 
“functional somatic syndromes” and “medically unexplained symptoms” (132).  
Complaints are common in the general population regarding musculoskeletal pains, 
digestive system, dizziness, sleep disorders, tiredness and other unspecific symptoms 
(133, 134). Ihlebaek et al. have registered high prevalence of SHC in the Norwegian 
population. Eighty percent reported pain from the muscular system, covering pain in 
all the regions of musculoskeletal origin like extremities, neck, back and shoulders. 
Sixty-five percent reported complaints that are characterised as “pseudo-
neurological” and consists of complaints as sleep problems, anxiety, headaches, 
menopausal symptoms as hot flushes, extra systoles and depression (134). However, 
general health complaints have not been measured earlier by SHC in patients with 
shoulder capsulitis. 
 
Outcome prediction of neck and shoulder disorders can be affected by psychological 
comorbidity besides other clinical findings (135). Some authors have suggested 
models explaining a relationship between psychosocial factors and development of 
musculoskeletal complaints and its chronification in association with work 
environment (136, 137). Patients with widespread pain more frequently have 
psychological problems and a worse prognosis regarding working capacity compared 
with patients with more localized problems (138). In patients with chronic pain, pain-
related beliefs are often associated with physical and psychosocial dysfunction (139). 
It is postulated that fear-avoidance is an essential feature of pain chronification in 





Experiencing outer environment as hostile, stressful or difficult is a characteristic of 
neuroticism. Strong associations have been found between generalized anxiety 
disorders, depression and neuroticism, which can be a significant predictor of 
subjective health complaints (141). Whether treatment outcome in frozen shoulder 
may be influenced by health complaints and neurotic symptoms has not been 




3. Aim and research questions 
 
The main aim of this thesis was to contribute to better management by the preferred 
treatment regime for patients with frozen shoulder (adhesive shoulder capsulitis) 
among general practitioners in primary care. This aim was to be fulfilled by 
suggesting an evidence based, pragmatic treatment and reliable follow-up of patients 




The three studies had the following specific aims: 
 
 
I To determine the reliability between two testers in examination of shoulder 
passive range of motion (PROM) bilaterally in participants with adhesive 
capsulitis using a validated measuring instrument, the plurimeter, over an 8-
week period. 
To determine if the measurement error remained the same during the 8-week 
period, measured three times 4 weeks apart. 
 
II  To elucidate the effect, if any, of multiple corticosteroid injections with 
distension, as compared to multiple corticosteroid injections alone and to 
treatment-as-usual. 
 
III To investigate whether subjective health complaints and neuroticism would 
predict treatment outcome at 8 weeks in patients diagnosed with frozen 
shoulder as measured by the Shoulder Pain and Disability Index (SPADI) and 





4. Design, material and methods 
 
We have conducted three studies with varying research methods. The first study is a 
longitudinal reliability study between two testers in which we registered passive 
range of motion at the gleno-humeral joint and investigated intertester reliability of 
measurements at three different time points. The second and main study is a 
randomised single blinded controlled trial in which we compared the effectiveness of 
intraarticular corticosteroid injection with and without distension to treatment-as-
usual. The third study is an observational study where we have investigated whether 
subjective health complaints and neuroticism could predict treatment outcome in 
frozen shoulder in terms of pain and function. 
 
4.1 Setting 
The study was conducted at a primary care clinic in Bergen, a coastal Norwegian city, 
with a population of about 250,000. Patients were referred by general practitioners in 
the city of Bergen and surrounding districts. The recruitment of the participants, 
follow-up and collection of data took place between September 2009 and December 
2013. Collection of data after one year of participation and until December 2014 was 
by postal communication. 
 
4.2 Participants 
During the patient’s first visit, it was confirmed whether the inclusion criteria were 
fulfilled and that there were no exclusion criteria. Before entering the study, every 
patient was given verbal and written information about the study. Patients were asked 




addressed envelope with their consent form duly signed within 14 days after the first 
visit or they could reply by SMS or e-mail. Patients had their second visit 14 days 
after the initial consultation, referred to as day one of the study. 
 
4.3 Inclusion and exclusions criteria   
To be included in the study patients had to be 18 years or older. They should have 
verbal and written knowledge of Norwegian, and there should be no contraindications 
for use of corticosteroids. Female patients in the fertile age group were asked about 
prevention and to take a pregnancy test if necessary. Passive range of motion had to 
be reduced with pain in external rotation, abduction and internal rotation. The 
reduction of motion had to be by more than 30% in two out of three shoulder 
movements and none of the three movements could be normal. All patients were 
having both pain and stiffness, and evaluated to be in phase II of frozen shoulder (59, 
142) (ref 142: page 306-307). Patients were excluded if they had diabetes, asthma, 
were pregnant or were breast-feeding mothers. The patient could not have other 
coexisting disorders in the arm or have a painful neck that could disturb pain and 




The first 50 patients who fulfilled the inclusion criteria and accepted to participate in 
the RCT were included in the reliability study.  
 
Study II 
We assessed 216 patients for eligibility for the effect project. Seventy patients did not 




up in the treatment-as-usual group and would need to wait for 8 weeks in case they 
wanted to receive treatment by steroid injections. Altogether 106 patients were 
included for randomisation. 
 
In the RCT 36 patients (35 analysed) were included in the steroid-only group (Group 
1), 34 patients (34 analysed) in the steroid group with distension (Group 2), and 36 
patients (36 analysed) were included in the treatment-as-usual group or control group 
(Group 3). One patient had to be excluded from the RCT due to change in measuring 
instrument from manual goniometer to plurimeter, a gravity inclinometer. At the 1-
year analysis for study II, one patient was excluded from steroid-only group (Group 1) 
for lack of postal reply. In steroid with distension (Group 2), 34 patients were analysed 
at 8 weeks and 32 patients at 1 year. Two patients dropped out (“no-reply”) from 
treatment-as-usual (Group 3) at the 1-year analysis (Figure 1).  
 
Study III 
In the third study, 105 patients were included. Both injection groups were merged into 
a single group (69 patients), and this intervention group was compared with treatment-
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Figure 1. Flow diagram for randomisation and follow-up 
 
35 participants were included 
in the ITT analysis 
34 participants were included 
in the secondary per-protocol 
analysis 
34 participants were included 
in the ITT analysis 
32 participants were included 
in the secondary per-protocol 
analysis 
36 participants were included 
in the ITT analysis 
22 participants were included 
in the secondary per-protocol 
analysis 
 
Study I: 50 first patients included  
Study II: 106 patients included 
Study III: 105 patients included  





4.5 Study I  
PROM was used in examination of intertester reliability in study I and as outcome 
measure in study II. Plurimeter -V, a validated gravity inclinometer (Plurimeter-V 
inclinometer; Dr. Rippstein, Zurich, Switzerland) was utilised as the measuring 
instrument for measurement of PROM. Abduction was measured with the patient in 
standing while external rotation and internal rotation was measured in supine lying 
position with arm in about 30 degrees of abduction. A plurimeter measures relative 
angle between two surfaces and is a light hand-held instrument. In the gravity 
referenced inclinometer, the starting position for the measurement is fixed, which is 
either 0° or 180°. We used 0 degree as the starting position to minimize placement 
error. Studies by Green et al. and Watson et al. have confirmed the validity and 
reliability of plurimeter for measuring PROM for shoulder (143, 144). The assessors 
measured the PROM motion in sideways passive elevation, passive medial rotation 
(by “hand behind back” method) and passive lateral rotation in degrees.  Studies have 
pointed out that “hand behind back” method does not actually measure true medial 
rotation (145, 146). Passive medial rotation (hand behind back) was measured in 
standing by measuring the distance of the patient’s radial tuberosity from posterior 
inferior iliac spine in centimetres. One assessor was blinded for the treatment 
received by the patient. This assessor received thorough information regarding the 
study and had been instructed in the procedure by the treating investigator. Only in 
the reliability study, PROM was also measured on the normal side on all visits. The 
end point was when the arm could not be moved more or the pain became unbearable. 
To avoid discrepancies in measurements due to affection of movements of thumb 
joints, we measured the distance in “Hand behind back” in centimetres between the 
styloid process of the radius to the posterior inferior iliac spine. This procedure with 
measuring PROM on the normal side with two testers was followed for the first 50 






4.6 Study II 
4.6.1 Randomisation 
The main study (study II) was an effect study, and all the included participants were 
randomised to one of three groups, the steroid injection only group (Group 1), steroid 
with distension (Group 2) and treatment-as-usual (Group 3). We allocated patients to 
the study groups by computerised block-randomisation with three permutations per 
block. One of the supervisors accomplished the randomisation without involving the 
investigator. Information on assigned grouping was put in envelopes with the patient 
code by the supervisor to be opened after each patient’s inclusion. It was therefore 
complete block randomisation.  
 
4.6.2 Intervention 
Intervention in this RCT project was applicable to study II only. In the steroid alone 
group, patients received 4 ml of total solution by intraarticular injection with 
Triamcinolone acetonide, 20 mg, 1 ml and Lidocaine 10 mg/ml, 3 ml. Patients in the 
steroid group with distension received 4 ml of Lidocaine and Triamcinolone 
intraarticularly and in addition 8 ml to 20 ml of physiological Natrium chloride 9 
mg/ml. The posterior approach by landmarks for intraarticular steroid injection was 
used. The following procedure was followed during the injections: The patient was in 
sitting position and the physician stood behind the patient slightly to the affected side. 
The left thumb was placed on the posterior corner of the acromion with index finger 
on the coracoid process. The needle was inserted 1-2 cm below the bony corner 
pointing towards lower edge of the coracoid process. The needle was pushed until it 
hit the bone. Injection was given slowly while keeping the needle in position. If there 
was a problem in emptying the syringe, the syringe was rotated while maintaining the 
pressure on the syringe, until it gave way. If there still was a problem in emptying the 




direction. The above procedure was then repeated (72, 74). The limiting factor for 
injecting amount of volume was pain and difficulty in injection. The treatment-as-
usual group served as comparison or control group and patients in this group could 
receive any other treatment other than corticosteroid injections or per oral 
corticosteroid medication. The control group remained without treatment with 
corticosteroids, in injection or tablet form, until 61 days, which was also the last day 
for outcome measurements. The time interval between the 1st and 2nd treatment was 7 
days, between the 2nd and 3rd treatment 10 days, and between the 3rd and 4th treatment 
14 days. Those receiving intraarticular injections were offered further continued 
treatment if desired after 8 weeks and if the patient himself/herself wished so due to 
residual pain. In case patients opted for different treatment e.g. physiotherapy, a 
referral was provided. After 8 weeks, similar facilities for corticosteroid injection or 
physiotherapy were made available to the control group as well.  
 
4.6.3 Outcome measures 
The primary outcome measure for the effect study was Shoulder Pain and Disability 
Index (SPADI), the secondary outcome measure was Numerical Pain Rating Scale 
(NPRS) and PROM the third outcome measure. The SPADI consists of 13 items and 
measures two aspects: pain and disability. A 5-item subscale measures pain and an 8-
item subscale measures disability. Each item has a score from 0 to 10. For pain, 0 
meant no pain and 10 unbearable pain. The total possible score is calculated in 
percentage and is 100. Higher score indicates increased pain and disability (124, 
147). We chose to use the newer version of SPADI using Numerical Pain Rating 
Scale, instead of the earlier version with Visual Analog Scale. SPADI has earlier 
been used in a variety of medical conditions in primary care (148, 149), in rotator 
cuff disease and shoulder capsulitis (150-153). High reliability has been reported in a 
systematic review with ICCs ≥0.89 (154) and Cronbach alpha above 0.90 proving 
high internal consistency (154, 155). SPADI has proved good construct validity, 




discriminating change in the condition without large floor or ceiling effect (124, 148, 
154, 156, 157). The minimal detectable change important to the patient is considered 
to be 8 points (156), but with repeated use of SPADI it is 18 points (158, 159). Any 
change less than this can be due to measurement error (147). For SPADI, being the 
primary outcome measure, we considered an outcome of 20% better or worse to be 
clinically significant. To be clinically significant, we accepted a change in outcome of 
20%, SPADI being the primary outcome measure.  A SPADI score of 70 would mean 
a change of 14 in total SPADI score. A difference in score of ≥ 10 has been accepted 
as clinically significant by other authors (66, 124). Buchbinder et al. had a variance at 
19.8 in SPADI as primary outcome measure (97). 
 
The 10-point Numerical Pain Rating Scale (NPRS) was used as secondary outcome 
measure to evaluate pain intensity, on an average of previous 7 days. Validated pain 
rating scales commonly used in clinical situations and clinical trials for measuring 
pain intensity are Visual Analogue Scale (VAS), Numerical Pain Rating Scale 
(NPRS) and Verbal Rating Scale (VRS). However, none of them has proved to be 
superior to the other (160, 161). The NPRS is, however, easier to use and has proved 
better compliance, better responsiveness and good applicability relative to VAS and 
VRS (162). Comparing VAS, VRS and NPRS in acute post-operative oral pain 
Breivik et al. found VAS to be better than VRS, but equal sensitivity was found 
between VAS and NPRS (163). In comparison between NPRS and VRS for episodic 
pain exacerbations in cancer patients, NPRS demonstrated higher reproducibility than 
VRS (164).  
 
The tertiary outcome measure was passive range of motion (PROM): PROM in 
abduction in standing, internal rotation by a pragmatic “hand behind back” method 





4.7 Study III 
For the third study, we used Subjective Health Complaints (SHC) and the 
Neuroticism component of the Eysenck Personality Questionnaire- Revised short 
form (EPQ-R. Degree of each complaint is rated on a 4-point scale in the SHC 
questionnaire (0= none, 1= some, 2= much, 3= severe. Total SHC sum scores for 29 
items and differentiated SHC scores for five subscales were calculated. The subscales 
are: Musculoskeletal (consists of headache, neck pain, back pain, pain in arms, 
shoulders, migraine and pain in feet on exertion); Pseudoneurology (comprising sleep 
problems, tiredness, anxiety, depression, dizziness, hot flushes and extra systoles); 
Gastrointestinal (consists of stomach discomfort, heartburn, ulcer/non-ulcer 
dyspepsia, stomach pain, flatulence, diarrhoea and obstipation), Flu (consists of flu, 
bad cold, cough/bronchitis) and Allergy (consists of asthma, chest pain, breathing 
difficulty, eczema and allergy) (131).  
 
The EPQ-R has four scales but we used only the Neuroticism component of the four 
scales. The four scales are: E (Extraversion vs. Introversion), N (Neuroticism or 
Emotionality), P (Psychoticism or Tough Mindedness) and L (Lie scale). In the short 
form questionnaire, Neuroticism (N) consists of 12 questions in yes and no format 
(165). 
 
4.8 Data collection 
4.8.1 Study I, The intertester reliability study 
Earlier intertester reliability studies have usually measured only affected (166-168) or 
only non-affected shoulders (169, 170). Participant numbers have usually been below 
35 (143, 167, 170-174), although as many as 50 patients has recently been 




were recruited in the intertester reliability study with age span from 38 to 75 years 
(mean age 52 years). Demographic data including side affected, duration of condition 
and previous treatments was collected before examination of PROM. Patients filled in 
schemas for NPRS and SPADI before PROM measurements. In patients having 
bilateral affection, the most affected side was chosen as the “affected” side and the 
less affected side as the non-affected side. Both testers had experience in measuring 
PROM on shoulder from an earlier pilot study and were experienced general 
practitioners. In addition, both had trained on use of plurimeter for measurement of 
shoulder motion before the commencement of the study. The measurement 
procedures were standardised beforehand. Tester B (investigator) always tested first 
and tester A afterwards. They kept their measurement records confidential and 
unavailable to each other during the study until all data for the reliability study had 
been collected.  
 
4.8.2 Study II - The randomised controlled trial 
The outcome measures data for this RCT was SPADI, NPRS and PROM, and was 
collected for all the 106 patients. The patients completed the SPADI and NPRS 
questionnaires on the first visit, at 4 weeks and 8 weeks, before they underwent 
clinical examination. At 12 months, the SPADI questionnaire was sent by post to the 
participants. On the first 50 participants, both testers measured the PROM on the 
affected and non-affected side at the first visit, at 4 weeks and at 8 weeks. From 
patient 51 and onwards the PROM was measured only on the affected side by both 
testers. Data for PROM was collected only for these three time points. By 8 weeks, 
we excluded one patient as participant in Group 1 due to change in measuring 





4.8.3 Study III - The predictive observational study 
For the purpose of this study, the two injection groups were merged into one group as 
no significant differences were found between them in Study II, hereafter called the 
intervention group (n=69). At inclusion, at 4 and 8 weeks, subjective health 
complaints were measured with the SHC questionnaire, neuroticism was measured 
with the Neuroticism (N) component of the Norwegian version of Eysenck 
Personality Questionnaire- Revised short form (EPQ-R) (165, 178, 179), and pain and 
function was measured with SPADI. Patients answered the questionnaires before 
examination at each visit. 
 
4.9 Analyses 
4.9.1 Study I  
We calculated intertester reliability that accounts for both relative agreement between 
testers and absolute measurement error between the measurements. For this purpose 
we used the Intraclass correlation coefficients (ICC model 2.1) for calculation of 
reliability, as this takes into consideration both systematic and random error (175) 
(page 103).  ICCs ranges between 0 and 1, but there are no fixed values for ICC to be 
considered as acceptable. Eliasziw and co-workers have however defined ICC values 
from moderate to excellent; ICC values >0.90 are considered excellent, ≥0.80 to 0.90 
as very reliable and ≥0.60 to 0.79 as moderately reliable (180). However, coefficients 
are dependent upon spread in data, as low spread in scores may give low ICCs despite 
little measurement error. A good spread in scores is required to demonstrate high 
agreement. Low values of ICC do therefore not necessarily indicate poor agreement, 
they can also be a consequence of restricted range of scores, and therefore agreement 




measurement error by absolute agreement, which is the actual difference in 
measurements and is expressed in degrees and centimetres.  
 
4.9.2 Study II  
Change in SPADI of ≥10 indicates clinically important change, improvement or 
worsening of shoulder pain and function (124). We calculated that a sample size of 
31 would have an 80% power to detect a difference in mean SPADI of ≥ 10 if 
standard deviation was ≤15.  We used repeated measures analyses of covariance 
(ANCOVA) and regression-based ANCOVA to analyze differences in outcome 
between the groups. We have analysed 4- and 8-weeks data as multiple follow up 
observations since these were not independent data. We have also differentiated 
between short-term (4 and 8 weeks) and long-term follow up (12 months). To extract 
the main effect of treatment between groups, we used repeated measure ANCOVA 
with 4 and 8 weeks observations as repeated measure, adjusting baseline differences 
between subjects using pretest as covariate (182) (p.197). Using 12 months 
observation as dependent variable, group as a categorical independent variable and 
pretest as covariate, we used another ANCOVA model with regression procedure to 
analyze the long-term follow-up data. To control for confounding factors, we added 
other independent variables to both ANCOVA models in an additional/secondary 
analysis. 
 
By subtracting the post-test scores (8 weeks and 12 months) from the baseline scores 
in the two groups and dividing it by standard deviation of the change scores, effect 
size (ES) for mean change in SPADI was deduced. An ES of 0.2 is small without any 
clinical importance, while an ES of 0.8 is considered large and of crucial practical 
and clinical importance (182). 
 
Keeping patients in their original allocations on randomisation in accordance with 




performed (184). There was very little missing data at short-term follow-up; for two 
patients at 4 weeks and one patient at 8 weeks. At long-term, data was lacking for six 
patients for 1-year follow-up. 
 
4.9.3 Study III 
We examined comorbidity and Neuroticism variables and had a close look at 
correlations between SPADI at 8 weeks and baseline SHC total and subscale scores 
as well as Neuroticism score. We chose appropriate baseline scores as predictors of 
outcome as measured by SPADI at 8 weeks by correlational analysis. The same 
analyses were repeated with change in SPADI from baseline to 8 weeks as outcome 
parameter because regression analyses can be affected by subtle baseline differences. 
Controlling for age, gender, intervention and duration of shoulder pain, we performed 
the multiple regression analysis with the items that correlated significantly with 
SPADI as predictors. We removed the insignificant predictors one by one by using 
backward elimination method for the multiple regression analysis. Both the initial and 
final models are presented. 
 
Software package IBM SPSS Statistics 22 for Windows was used for all statistical 
analyses. 
 
4.9.4 Missing values 
In the first study, we chose to include consecutively patients between 2 and 51. The 
first patient was excluded from further participation in steroid-alone group (Group 1) 
because of change in the measuring instrument, which was a crucial part in enhancing 
the quality of measurements. In the second study, all 106 patients were analysed on 
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5.1.1 Study I 
The reliability study with two testers that measured passive range of motion (PROM) 
three times (at inclusion, after 4 and 8 weeks) in 50 patients with adhesive capsulitis 
in stage II, demonstrated from very good to excellent intertester reliability. We 
achieved excellent intertester reliability on the affected side at all three time-points. 
No change was observed on the unaffected side while the affected side showed 
change in measurements probably caused by either general improvement or treatment 
or a combination of both. The variation in measurement errors was small, between 
~5°-7° at all three time-points while measuring passive abduction, passive external 
and internal rotation on the affected shoulder. Small measurement error was 
registered during measurement of passive abduction in the normal arm (~1.5°-2°) and 
hand behind back (~1cm -2 cm) at all three time-points in both arms. 
 
The ICCs values (ICCs ≥0.83 - 0.96) were highly reliable for the affected side at all 
three time-points. The normal side showed slightly lower ICC values than the 
affected side at the third visit only. 
 
The absolute measurement error found in our study was small and stable throughout 
the test period. The smallest detectable changes from pre-test to 8 weeks were 
statistically significant for the affected arm. 
 
5.1.2 Study II 
We randomised 106 patients for participation in the RCT. The group who received 
injection with corticosteroid alone (Group 1) had 36 patients, the corticosteroid and 
distension with saline group (Group 2) had 34 patients, and the treatment-as-usual 






Table 1. Baseline characteristics of patients* 
 
Characteristics Steroid injection 
alone (Group 1) 
Number and % 
n=36 
Steroid injection 
and saline  
(Group 2) 





Number and %  
n=36 
Mean age in years  
(SD) 
52 (8.3) 53 (9.2) 54 (6.9) 
Female 
 
21 (58%) 21 (62%) 19 (53%) 
Duration in 
months 
Median (range)  
7.5 (2.0 – 18.0) 7.0 (3.0 – 37.0) 6.0 (3.0 – 24.0) 
Concurrent neck 
pain 
16 (44%) 15 (44%) 16 (44%) 
Trauma to 
shoulder  
2 (6%) 11 (32%) 3 (8%) 
Previous shoulder 
treatment 
15 (42%) 22 (65%) 13 (36%) 
Analgesics 
 
19 (53%) 14 (41%) 11 (31%) 
Participants on 
sick leave 
17 (50%) 16 (47%) 15 (42%) 
SPADI  
 
64 61 62 
 






Except for one patient in Group 1, there was no dropout and all patients completed 
the specified intervention until 8 weeks (Figure 1). Altogether 100 patients (95%) 
answered the SPADI questionnaire at 1-year follow-up. We did not perform interim 
analysis during the study. The baseline characteristics of the three groups were 
comparable concerning age, gender, mean duration of shoulder pain, concurrent neck 
pain, previous frozen shoulder, number of affected right side and dominant side and 
sick leaves (Table 1).  
 



















Group comparisons for SPADI: 
two intervention groups vs. control group




Thirty-five patients in Group 1 and 34 patients in Group 2 received four injections 
each within a period of 8 weeks. All three groups showed clinically significant 
change in SPADI from baseline to 8 weeks (>14 points improvement). Both 
intervention groups improved significantly more as compared to Group 3. After 12 
months, there was no difference between the three groups (Figure 2). Similarly, there 
was a significant improvement in NPRS at 8 weeks for both intervention groups, but 
less in Group 3. Change in PROM for abduction from pre-test to 8 weeks was slightly 
better between the intervention groups (in Group 1: 54° increased to 69° i.e. 15° 
increase; in Group 2: 51° increased to 72°, a 21° increase) than in Group 3 (51° 
increased to 57°; i.e. 6° increase). Similarly, external rotation for Group1 increased 
by 18°, for Group 2 by 18°, and 7° for Group 3. The increase in PROM for internal 
rotation for Group 1 was 18°, for Group 2 19° and for Group 3 it was 7°.  
 
There was no difference between the two intervention groups for effect size (ES) 
regarding SPADI at 8 weeks (ES 1.2) and at 12 months (ES 0.3 and 0.4). However, at 
12 months, all three groups were equivalent, the change was equally large in all 
groups and no statistically significant difference was found between the three groups.  
 
5.1.3 Study III 
The baseline characteristics of patients, including baseline SPADI, was the same for 
the intervention group and the control group. Contrary to our expectation, low 
prevalence of subjective health complaints existed when descriptive scores for SHC 
and for Neuroticism at baseline and 8 weeks were analysed. We were interested in 
finding out whether prediction of outcome in frozen shoulder was possible in 
presence of comorbidity as measured by SHC and Neuroticism. Using relevant 
variables, possible correlation was analysed and the most appropriate variables were 
then used in the regression analysis. Statistically significant Pearson’s correlation 
coefficients for SHC total score at baseline versus SPADI at 8 weeks was 




subscale in SHC at baseline (p=0.009). SPADI at baseline and female gender also had 
a significant correlation. The total SHC score became insignificant after removing the 
Pseudoneurology subscale from the baseline total SHC score, proving that 
significance was due to the Pseudoneurology subscale. Neuroticism did not show any 
correlation with outcome measure at 8 weeks, while statistically significant 
correlation was shown with change in SPADI from baseline to 8 weeks by female 
gender and group allocation. None of the other SHC subscales at baseline returned 
significant correlation coefficients with SPADI. We chose therefore to keep only the 
Pseudoneurology subscale as predictor and not the total SHC baseline score in the 
multiple regressions analysis. We did not find any correlation between baseline 
Neuroticism and SPADI or change in SPADI after 8 weeks.   
 
Multiple regression analysis with SPADI at 8 weeks as the dependent variable, 
controlling for age and gender, revealed a statistically significant predictive value for 
Pseudoneurology in SHC at baseline (p<0.001) and group allocation (p<0.001). 
Shoulder pain duration did not show any statistically significant predictive value. 
 
Group allocation exhibited statistically significant predictive value for change in 
SPADI from baseline to 8 weeks (p<0.001). No significant predictive value at 8 
weeks for change in SPADI was exhibited by baseline SHC scores, while statistically 
significant predictive value for change in SPADI from baseline to 8 weeks (p<0.01) 






6.1 Methodological considerations 
6.1.1 Design 
This thesis is based on three studies involving examination and treatment of patients 
diagnosed with frozen shoulder. The first study is a prospective intertester reliability 
study where the participants were followed over time and outcome of interest 
registered by two testers. The second study is an RCT comparing outcome after 
intervention with a control group, and the third study is a prospective observational 
study exploring prediction of outcome in frozen shoulder in presence of comorbidity.  
 
Study I 
Correct measurement of passive range of motion is important for both diagnosis and 
in follow up of patients with painful and stiff shoulders as an outcome measure to 
consider effectiveness of given treatment (42-45). We examined PROM of the first 
50 patients recruited in the main RCT, regardless of group allocation to avoid 
channelling bias, which occurs when patient prognostic factors decide the group 
placement of the cohorts (185). All recruited patients had confirmed diagnosis of 
shoulder adhesive capsulitis/frozen shoulder, and were mainly in phase II with both 
pain and reduced shoulder movement. We used standardised diagnostic criteria as 
described in the literature, as it is essentially a clinical diagnosis (8, 186, 187). Two 
testers measured PROM in both the affected and non-affected shoulder at three time-
points. To reduce bias, we had standardised the measurement procedure and the 
testers had undergone training in measurement of PROM to reduce intertester 
variability (143). However, there were some limitations regarding data collection. 
The investigator himself (tester B) was one of the data-collectors and carried out 
measurements. This might have introduced interviewer bias (188) in data collection 




inclusion, which may reduce internal validity (189). To avoid this, only the patient’s 
identity number was written on the data registration sheet and the page was removed 
right after the measurement was finished. The two testers measured PROM in the 
same pattern, i.e. tester A always measured after tester B, possibly inducing 
systematic error.  
 
Study II 
A selection bias in the material by excluding patients with diabetes and asthma might 
have been unknowingly introduced, although this factor would have been equally 
distributed in all three groups in the RCT. We were concerned during the decision 
making process about inclusion and exclusion criteria, that asthma patients might 
drop out of the study due to need for treatment with steroids during an exacerbation 
of asthma, as use of steroids in any form except for intervention would have led to 
exclusion from the study. Diabetes was also an exclusion criterion in this study. Some 
diabetes patients get larger fluctuation in their blood sugar level due to corticosteroid 
injection, making it difficult to regulate, and this could have caused dropout. It is 
known that diabetes patients are about five times more prone to develop frozen 
shoulder than the normal population (190-192). Patients with diabetes are generally 
more resistant to interventions (6, 20, 59, 193). Yet another criterion was to exclude 
patients who could not express themselves in Norwegian. To include these patients 
would have required much more administrative work for arranging translators and 
arranging the consultations at different timings for the blinded assessor. This would 
have caused considerable economic burden on the project, which was out of reach for 
this study. The included patients had to have more than 30% reduced PROM and 
none of the three passive shoulder movements for abduction, external rotation and 
internal rotation should be normal. We thereby excluded patients with milder frozen 
shoulder and most patients included in the study were therefore in stage II with 
SPADI above 60. This increased the recruiting time substantially and it took a total of 
4 years to recruit 106 patients. Of the eligible participants, 40 patients declined to 
participate for fear of ending up in the control group, further delaying their treatment 




practitioners and the patients had probably an expectation of receiving treatment 
straight away. Being asked to participate in a trial became something unexpected and 
induced hesitation to participate. On one hand, it delayed the recruiting process; while 
on the other hand, it introduced bias in choice of population as fair representatives of 
this condition. It is possible that some of the patients who declined participation in 
the study had a lot of pain and did not want to wait for treatment. However, most 
patients with frozen shoulder contact health services in phase II and we thus consider 
our study population as representative of the general population with this condition. 
The study investigator was involved in carrying out the injections and that may have 
introduced bias. While giving injection, patients were placed in a way that they were 
unable to see the injection syringe, almost 1/3 of the patients guessed wrong group 
when asked about group belongingness after the intervention period. We consider this 
successful blinding of the patients in the intervention group regarding given 
treatment. The patients themselves filled out the questionnaires regarding degree of 
pain and disability without the presence of study personnel, and hopefully with little 
or no Hawthorne effect. Hawthorne effect refers to the phenomenon that being 
participant in the study has a positive effect on participant’s behaviour and thereby 
results. 
 
We divided the participants in three groups, two intervention groups and one 
treatment-as-usual-group who served as control group with usual conservative 
treatment, except for steroids in any form. We did not have a placebo group, which 
we think would have increased the internal validity of the study. We considered it 
unethical to have a placebo group when we planned the protocol, as some patients 
experience very strong shoulder pain and expect to be offered pain relieving 
treatment (104). One of the general problems in effect studies is to ensure that the 
control group remains without exposure or only to the specified exposure, which we 
were able to monitor in our study with the treatment-as-usual group. This was 
controlled on visits at 4 weeks and 8 weeks and none of the patients were exposed to 





An important aspect of this study is that it is a pragmatic randomised controlled trial, 
well suited to and in accordance with current practice of treatment for frozen shoulder 
in general practice and we have tried to reduce the pitfalls (189, 194). The pragmatic 
part in this RCT was having one of the investigator as also the one who gave 
injections and who was one of the assessors. This may introduce bias (interviewer 
bias), but may also be positive in some respects. The practical hurdles in having 
someone from outside the clinic to do injections included a need for different 
locations to carry out the procedures and more importantly unavailability of qualified 
person to do the procedures. We did not have any dropout for the first 8 weeks of the 
trial. The one dropout was due to change in measurement instrument and non-
compliance was not the reason. At 1-year follow up, 100 (95%) patients answered the 
questionnaire, which is very good and maintained the strength of study.  
 
Although accuracy of intraarticular steroid injections is debated (75-78, 81, 83, 195), 
the degree of difference between ultrasound guided and injection by anatomical 
landmarks is very unclear (196). Most of the studies involving distension are 
performed in secondary care using imaging techniques. We chose to give injections 
by anatomical landmarks using a common intraarticular injection technique as it is 
practiced in primary care in Norway, i.e. by posterior approach. Most patients with 
frozen shoulder are treated in primary care and it was therefore natural to use the 
same treatment procedure that is in common use in general practice. Similarly, we 
used 20 mg Triamcinolone dose, which is common to use in treatment of frozen 
shoulder in general practice. Morale is to use the minimum effective dose. Former 
studies did not find any difference in effect between low and high dose (197, 198). 
Furthermore, multiple injections were used in this study, in accordance with the 
common practice in general practice in treatment of frozen shoulder. A review has 
favoured multiple injections in the treatment of frozen shoulder (26). Intraarticular 
injections were given with increasing time gap from 1 week, 1 ½ week and 2 weeks. 
Previous studies using multiple injection have used injections from once a week to 
once in 2 weeks and once in 4 weeks, with assessment of outcome measures varying 




Norwegian primary care. In summary, the combination of using injection techniques 
by anatomical landmarks, low dose of 20 mg Triamcinolone acetonide and use of 
multiple injections is the same as currently practised in primary care.  
 
Study III 
The patients included in this study are the same as mentioned in study II. The 
intervention group constitutes both the steroid intervention groups from the RCT, 
combined to one group. In the SHC questionnaire we omitted the scoring of 
frequency of complaints the last 30 days as it was difficult for the patients to 
remember this reliably. This has probably avoided recall bias. Scoring for 
neuroticism in EPQ-N questionnaire is dichotomised to yes/no answer and not graded 
in degree of symptoms. This might have affected the results as patients with slight 
anxiety or slight symptoms might have answered no. On the other hand, slight 
symptoms might not in any way have affected the outcome.  
 
Validity 
Validity refers to being genuine or valid. The Oxford dictionary defines it as “the 
quality of being logically or factually sound; soundness or cogency.” In this thesis, 
validity also refers to originality and trustworthiness of our collected data. The 
internal and external validity will be discussed here, as it is applicable to the studies 
included in this thesis.  
 
Internal validity 
Internal validity refers to how well the collected data corresponds to results.  It may 
also refer to the reverse i.e. how well the results fit the original data. In other words it 
may reveal that a causal relationship exists between the independent (for example 
given treatment) and dependent variable (181) (page 75). It also addresses the issues 
of the study being free from bias or systematic errors, how well confounding is 
avoided and the results are based on its bias free data. Randomisation is a good tool 
to reduce bias and confounding. Confounding refers to a variable, which changes 




will increase internal validity. Randomisation with blinding of both assessor and 
patients at inclusion minimises bias and increases internal validity (181) (page 75-
77).  
 
In study I, the investigator was one of the data collectors and remembering group 
allocation at the time of inclusion might induce interviewer bias if the investigator 
had a presumption towards a particular result. To avoid this, only the identity number 
was written on the PROM registration sheet and was removed after measurements. 
Having a big enough sample size and large number of measurements producing an 
overall good result contributes to increased internal validity. A systematic error might 
have been introduced while performing measurements as tester A always measured 
after tester B. Pain provocation after tester B had taken measurements might have 
affected measurements by tester A since the criteria for PROM were pain and 
stiffness. Using another tester or in other words having the study as double blind 
would have solved this problem. This would have of course change the actual study 
in many ways. Practically and economically, it was not feasible to do so. On the other 
hand, having an experienced investigator who is well versed with measuring PROM 
and treating this group of patients has been a great advantage. The dropout rate in the 
first 8 weeks has been under one percent and has maintained sample size and strength 
of the study. As assessor B was also the investigator in the study that, generates trust 
and might have led to reduced dropout rate. One can also trust the performed 
procedures, which increases internal validity of the study. 
 
External validity 
External validity is about certainty of applicability of results from this study to 
patients with frozen shoulder in other studies or in general, or in other words, 
generalisation of the results. One can generalize to groups, settings or times or across 
groups if multiple subgroups of population, settings or times are studied (181) (page 
87). Patients with asthma may require corticosteroid during an exacerbation and use 
of corticosteroid in patients with diabetes may make blood sugar levels very unstable 




diabetes from the study, for fear of dropout since use of corticosteroid in any form 
was contraindicated. The exclusion of these patients affects external validity of this 
study. Excluding patients who could not speak or understand Norwegian may also---
affect the generalisability of the study. However, by chance, all patients eligible for 
participation could speak and understand Norwegian, and external validity for this 
reason was therefore not affected. In study I, the standard error of measurement was 
small and reliability was from very good to excellent which increases generalisation 
of the study due to its applicability in measuring PROM for follow-ups and research. 
We did not continue registration of the SHC and EPQ-N questionnaire past 8 weeks, 
which limits the generalisation of the results because frozen shoulder is a chronic 
condition and often needs long follow up. This may affect the external validity of the 
study. Using injection techniques by anatomical landmarks, low dose of 20 mg 
Triamcinolone acetonide and use of multiple injections is the same as currently 
practised in primary care ensuring the usefulness of results in general practice. 
 
6.2 Discussion of results 
The three studies in this project form a continuum of the research project on shoulder 
capsulitis from using range of motion as a reliable follow up tool (study I), to 
management of the condition by intraarticular injections with or without distension 
(study II), taking into consideration possible impact of comorbidity on interventional 
outcome of treatment for frozen shoulder (study III). 
 
The baseline characteristics were similar in the intervention groups and the treatment-
as-usual group, and one of the testers did not know the patients’ group belonging.  
 
The first study focused on the reliability of measurement of passive range of motion 
in patients with frozen shoulder. We performed a large number of measurements in 




unaffected side at three different time points. Based on several factors described 
below, the results in study I are comparable with or better than other reliability 
studies measuring shoulder ROM (143, 166, 173, 200). This might be due to large 
number of measurements measuring also on the normal side and beforehand training 
in measurements of assessors. The standard error of measurement was small and 
reliability between the two testers was very good to excellent. The standard error of 
measurement is a measure of how much measured test scores are spread around a 
“true” score. The standard error of measurement is especially meaningful to a test 
taker because it applies to a single score and it uses the same units as the test (168).  
 
The variation in measurement errors in our study was small, between ~5°-7° on all 
three time-points while measuring passive abduction, passive external and internal 
rotation on the affected shoulder, and in measurement of external and internal 
rotation on both sides. The ICCs values (ICCs ≥0.83 - 0.96) were highly reliable for 
the affected side on all three time-points in spite of the fact that the participants at 
baseline had quite high pain intensity (scored between 5 and 9 on NPRS). This 
increases the generalisability of the study and results from the study provides support 
for that PROM measured with a plurimeter can reliably be applied in clinical practice 
as well as be used as an outcome measure in research. It indicates that measuring 
PROM reliably is important in diagnosis and in follow up of patients with frozen 
shoulder, especially in an outpatient setting when a patient is examined and followed-
up by different therapists. However, we did not perform an intratester reliability 
study. That would have increased the applicability in single practices as well. 
Furthermore, active movements were not measured either. Active movements involve 
trick movements unconsciously to overcome pain and stiffness. Some patients stop 
long before pain is uncomfortable for fear of pain provocation as it is very common 
to have “after- pain” after activity in frozen shoulder. Factors like fear for pain and 
trick movements would make interpretation of true ROM very difficult and probably 
unreliable and therefore it was decided not to include active movements in the ROM 
measurement protocol, even though some studies have shown active range of motion 





The participants in our study are representative for patients with frozen shoulder, 
having a mean age of 53-54 years, and the majority being female as they usually are 
more affected than men. The use of analgesics in the treatment-as-usual group was 
16% less than the intervention group. We believe that this had little or no impact on 
the results, as most pain reduction happened in the first 8 weeks in the intervention 
group. Twice as many participants in the treatment-as-usual group were on sick 
leaves. This could have affected the economic outcome. Unfortunately, we did not 
calculate any economic impact of intervention in this study so far, even though it 
would have been interesting to do so. There are probably large potentials in savings 
for patients on sick leaves if this condition can receive early treatment. The high costs 
for society associated with sick leave and disability due to adhesive capsulitis indicate 
that there is a clear need to determine the most cost-effective interventions for this 
disorder (202). 
 
The included patients in the study represent a patient population in phase II of frozen 
shoulder, being in the painful phase with reduced function and with a SPADI score at 
circa 62. There was only one drop out at short-term i.e. at 8 weeks and 95% answered 
the questionnaire at one year. We had expected a dropout at 10%, but in our study, it 
was far less. The study has therefore maintained good strength throughout.  
 
A review regarding effect of intraarticular steroid injection concludes: “Intra-articular 
steroid injection is effective and safe for frozen shoulder and relieves pain, improves 
functional performance, and increases range of motion” (203). Former studies have 
claimed good results with distension (97). The difference in outcome in terms of 
SPADI and NPRS at 4 and 8 weeks between the two intervention groups was not 
statistically significant. It has been argued that since former distension studies did not 
observe any difference in outcome, the major effect seemed due to corticosteroid (98, 
101). The study by Buchbinder et al. using 21-80 ml of saline (median 43 ml), argued 
that the distension must be large enough to have an effect (97). Tveitå et al. who 




(101 177) contradicted the statement by Buchbinder et al. They questioned further 
injecting of saline, as it would leak out of the joint anyway.  
 
Our study did not find any difference in outcome between using distension and not, 
making it possible to recommend use of multiple injections with moderate dose of 
steroids without distension. A systematic review and meta-analysis did not find any 
superior effect of dilatation at long-term. Aspects of approaches, imaging guiding 
techniques and doses of distension were not found to modify treatment effectiveness. 
In conclusion, distension of the gleno-humeral joint provides a similar long-term 
efficacy to all reference treatments (103). Another systematic review and network 
meta-analysis comparing efficacy of intraarticular steroid injection and distension in 
patients with frozen shoulder conclude that intraarticular steroid injection is as 
effective as distension in shoulder-function improvement and reduction of pain (102). 
This is in accordance with our conclusion. Results of intervention with or without 
distension may be equivalent to guided injections. It is important to follow the correct 
injection technique, i.e. to have bone contact while injecting to have a successful 
outcome by giving intraarticular injection by anatomical landmarks (142, 204). 
 
We used anatomical landmarks for intraarticular injections both for patients without 
distension and with distension. We could not be sure whether the medication had 
been delivered intraarticular or extra articular. It was not certain whether capsular 
rupture had taken place, even if the intention was a non-capsular rupture dilatation.  
Results in our study by landmarks are still comparable with studies using fluoroscopy 
or ultrasound (101), even though others maintain to have better results with guided 
injections (81). A two weeks superiority of ultrasound-guided intraarticular injection 
as compared to injection by landmark guidance (195) is too little considering the 
extra resources employed in using guided injections. 
 
Three patients were operated and 12 patients chose to receive intraarticular 
corticosteroid injections in the time interval between 8 weeks and 1 year. We did not 




SPADI, and a secondary per-protocol analysis performed excluding the 15 patients 
that did not follow the initial treatment-as-usual protocol after the 8-week period. 
This means that the results of the trial are still valid though the sample size of the 
Group 3 was reduced. 
 
Frozen shoulder has been considered to be a self-limiting disease (12, 23, 38). The 
condition lasts for about 2 to 3 years, and 40% of patients may still have residual 
disability and pain several years afterwards (21, 40, 67). The research community 
tend to focus on the long-term results that might lead to passive attitude towards early 
management of this condition. This has probably led to long standing wait and see 
attitude. Shoulder pain and stiffness is accompanied by severe disability often 
resulting in absenteeism from work, inability to perform leisure activities, and 
utilization of health care resources (202). Patients find it difficult to sleep, to perform 
activities of daily life or to take care of personal hygiene, finding this disorder most 
disturbing, all due to pain and stiffness. While under treatment, patients express their 
extreme satisfaction for being able to sleep without being awakened by pain. Most 
patients have considerable relief from both pain and stiffness during the first 8 weeks 
of treatment. Even if patients are interested in long-term relief as well, they value this 
early relief very much. Thus, from patients’ perspective, a short-term relief is 
extremely valuable which takes them back to their somewhat normal daily routine. 
 
Literature describing economic burden of frozen shoulder is scanty. According to 
data from 2013 for Global Burden of Disease Project and the Norwegian Directorate 
of Health, musculoskeletal disorders caused the highest production cost mainly due to 
sick leaves (205). Putting suffering due to pain and disability aside in frozen shoulder 
disorders, the major economic impact is from sick leave. This is an extra burden 
particularly for self-employed single person businesses. Literature regarding 
economic evaluation in frozen shoulder is mainly related to economic burden for 
given conservative treatment. Van den Hout et al. found that the burden due to 
adhesive capsulitis was estimated at 0.048 quality adjusted life years and €4,521 per 




calculated the cost difference between the intervention and the placebo group. 
Difference in monthly non-health care cost favoured the physiotherapy group ($14.6 
AUD), largely due to work absence costs that outweighed the travel and time costs to 
visit the physiotherapist (202). A review could not conclude regarding the most 
economical intervention since the cost of interventions varied widely depending upon 
the setting. i. e. primary care versus secondary care; type of intervention and whether 
a specialist or a physiotherapist performed the intervention. In UK, cost of 
intraarticular steroid injection by anatomical landmarks varied from £36 to £139 and 
for guided injection from £99 to £476. With addition of physiotherapy, these costs 
varied from £121 to £607 (69). To my knowledge, in Norway, the cost for 
intraarticular steroid injection in shoulder varies from NOK 350 to NOK 500 with 
physicians and specialists under National Health Scheme, and up to NOK 1500 for 
privately practicing physiotherapists or physicians. 
 
Neuroticism did not show any correlation with the outcome measure at 8 weeks, 
while statistically significant correlation was exhibited with change in SPADI from 
baseline to 8 weeks by female gender and group allocation. Pseudoneurology in SHC 
at baseline (p<0.001) and group allocation (p<0.001) demonstrated statistically 
significant predictive value using SPADI at 8 weeks as dependent variable in a 
multiple regression analysis. We had expected that the Musculoskeletal subscale 
would reveal predictive value with SPADI as outcome since it has components of 
pain, which we expected to matter in this scenario. Very often pain and stiffness go 
hand in hand in frozen shoulder, although this may not always be the case. The 
possible explanations may be that psychological distress seems to matter more than 
stiffness in frozen shoulder as demonstrated by Bagheri et al. (207). Frozen shoulder 
and psychological conditions seem to have a correlation, as there is more self-
reported pain and disability among patients having both conditions simultaneously 
(208). Engebretsen et al. (209) found education as the most consistent predictor of 
outcome as measured by SPADI, along with work status at 1-year follow up in 
subacromial shoulder pain.  Other parameters that predicted outcome were baseline 




correlation, had we gathered data on SHC and Neuroticism before patients received 
their diagnosis and explanation of the condition. However, this would have been a 
tedious job to achieve in around 200 possible participants before inclusion. Anxiety 
about the condition seems to disappear after the patients received the final diagnosis 
and explanation about natural course of the condition. There is also a possibility that 
SHC and Neuroticism are not able to measure psychometric parameters unless they 
are highly accentuated, as was also revealed by Ursin et al. (210). Absence of 
correlation of Neuroticism with outcome measure is in accordance with other studies 
(211). Literature does seem to reveal that psychological parameters can affect the 
outcome (15, 135-137), but our study could not demonstrate it. 
 
Every pharmacological treatment can have side effects. Corticosteroids in injection 
form can give side effects that generally are transient (212). Most common of these 
are flushing with redness and feeling of swelling on face, discolouration of skin 
commonly seen at places where there is little subcutaneous tissue, and sometimes 
women in productive age can get disturbances in menstruation cycle. Simultaneous 
intake of anticoagulating agents can cause bleeding under skin and give bluish 
discolouration. Intraarticular or periarticular infection are most feared but are seldom, 
varying from 1 in 14000 - 50000 injections with aseptic technique (213, 214). In this 
trial 29% of patients in the intervention group experienced flushing and after-pain. 
No other side effects were reported. This is an acceptable degree of side effects. This 
practice of using multiple steroid injections for frozen shoulder in primary care can 







This thesis has contributed to more insight into importance of correctly measuring 
passive range of motion, treating optimally and pragmatically by simple conservative 
means and follow-up of patients with frozen shoulder. It has shed light on what 
comorbidty might mean for outcome and rate of recovery from frozen shoulder. 
 
 Measuring passive range of motion in patients with frozen shoulder using a 
plurimeter has demonstrated very good intertester reliability. 
 Examining passive range of motion by this method can be used as a reliable 
outcome measure clinically as well as in research. 
 Multiple corticosteroid injections with or without distension in series, with 
increasing intervals during an 8-week period had better outcome than 
treatment-as-usual (control group) in our intention to treat RCT. 
 The long-term outcome at 12 months did not differ between intervention and 
control groups, highlighting the natural course of the condition  
 Treatment outcome, as measured by SPADI at 8 weeks in frozen shoulder, was 
predicted by the Pseudoneurology subscale in Subjective Health Complaints, 
but not by change in SPADI from baseline to 8 weeks.  
 Psychological factors do not predict rate of recovery as reflected by change in 
SPADI as measured by Subjective Health Complaints and Neuroticism. 





8. Implications and recommendations for future 
research 
8.1 Clinical implications 
This thesis has contributed in understanding successful management of frozen 
shoulder in primary care using simple conservative means by a pragmatic approach. 
 
 Passive range of motion can be measured accurately by plurimeter for both 
diagnostics and follow up of patients with frozen shoulder, and is easy to 
implement in clinical practice and research. 
 It is not necessary to use distension in treatment of frozen shoulder with 
intraarticular corticosteroid injection, saving patients from the discomfort of 
adding saline. 
 Even if the long-term results are the same, it is the early painful months which 
often mean most to the patients suffering from frozen shoulder. Patients can 
therefore be spared from unnecessary pain and markedly reduced function and 
quality of life. They should be offered this alternative of treatment by 
intraarticular steroid injections in the painful phase. 
 Comorbidity as measured by Subjective Health Complaints and Neuroticism 
may not necessarily affect outcome negatively if patients receive thorough 





8.2 Future research 
 High quality research with multi-armed preferably multi-centred adequately 
powered randomised controlled trials that may lead to diagnostic consensus 
and consensus regarding best conservative management strategy for frozen 
shoulder.  
 To compare outcomes with multiple intraarticular corticosteroid injections: 
anatomical landmark versus ultrasound or fluoroscopically guided with and 
without distension with added physiotherapy comparing group treatment, 
individual based treatment and self-treatment (exercises) after instructions 
including patients with primary (idiopathic) and secondary frozen shoulder. 
 Furthermore, management of primary and secondary frozen shoulder in 
painful phase can also be compared.  
 Assess the role of high quality patient information/education regarding frozen 
shoulder and self-management at an early stage. 
 Outcomes should measure pain, function, sleep and quality of life with 
standardised validated questionnaires. 
 Future research should examine the impact multiple corticosteroid injections 
have on sick-leave and economic burden as compared to other conservative 




9. Source of data/References 
1. Robinson CM, Seah KT, Chee YH, Hindle P, Murray IR. Frozen shoulder. J Bone Joint Surg Br. 
2012;94(1):1-9. 
2. Zuckerman JD, Rokito A. Frozen shoulder: a consensus definition. J Shoulder Elbow Surg. 
2011;20(2):322-5. 
3. Codman EA. The shoulder: rupture of the supraspinatus tendon and other lesions in or about 
the subacromial bursa. Boston: Thomas Todd co.; 1934. 
4. Neviaser JS. Adhesive Capsulitis of the Shoulder - a Study of the Pathological Findings in 
Periarthritis of the Shoulder. J Bone Joint Surg. 1945;27(2):211-22. 
5. Wiley AM. Arthroscopic appearance of frozen shoulder. Arthroscopy. 1991;7(2):138-43. 
6. Dias R, Cutts S, Massoud S. Frozen shoulder. BMJ. 2005;331:1453-6. 
7. Bunker TD, Anthony PP. The pathology of frozen shoulder. A Dupuytren-like disease. J Bone 
Joint Surg Br. 1995;77:677-83. 
8. Nagy MT, Macfarlane RJ, Khan Y, Waseem M. The frozen shoulder: myths and realities. Open 
Orthop J. 2013;7:352-5. 
9. Omari A, Bunker TD. Open surgical release for frozen shoulder: Surgical findings and results of 
the release. J Shoulder Elbow Surg. 2001;10(4):353-7. 
10. Bunker TD. Time for a new name for 'frozen shoulder'. Br Med J (Clin Res Ed). 
1985;290(6477):1233-4. 
11. Lewis J. Frozen shoulder contracture syndrome - Aetiology, diagnosis and management. Man 
Ther. 2015;20(1):2-9. 
12. Lundberg J. The frozen shoulder. Clinical and radiographical observations. The effect of 
manipulation under general anesthesia. Structure and glycosaminoglycan content of the joint 
capsule. Local bone metabolism. Acta Orthop Scand. 1969:Suppl 119:1-59. 
13. Tighe CB, Oakley WS, Jr. The prevalence of a diabetic condition and adhesive capsulitis of the 
shoulder. South Med J. 2008;101(6):591-5. 
14. Guyver PM, Bruce DJ, Rees JL. Frozen shoulder – A stiff problem that requires a flexible 
approach. Maturitas. 2014;78(1):11-6. 
15. Wolf JM, Green A. Influence of comorbidity on self-assessment instrument scores of patients 
with idiopathic adhesive capsulitis. J Bone Joint Surg Am. 2002;84-A(7):1167-73. 
16. Bridgman JF. Periarthritis of the shoulder and diabetes mellitus. Ann Rheum Dis. 1972;31(1):69-
71. 
17. Hand C, Clipsham K, Rees JL, Carr AJ. Long-term outcome of frozen shoulder. J Shoulder Elbow 
Surg. 2008;17(2):231-6. 
18. Arkkila PE, Kantola IM, Viikari JS, Ronnemaa T. Shoulder capsulitis in type I and II diabetic 
patients: association with diabetic complications and related diseases. Ann Rheum Dis. 
1996;55(12):907-14. 





20. Zreik NH, Malik RA, Charalambous CP. Adhesive capsulitis of the shoulder and diabetes: a 
meta-analysis of prevalence. Muscles, Ligaments and Tendons Journal. 2016;6(1):26-34. 
21. Shaffer B, Tibone JE, Kerlan RK. Frozen shoulder. A long-term follow-up. J Bone Joint Surg Am. 
1992;74:738-46. 
22. Cyriax J. Textbook of Orthopaedic Medicine. Diagnosis of Soft Tissue lesions 7ed. London: 
Baillie're Tindall; 1982. 
23. Reeves B. The natural history of the frozen shoulder syndrome. Scand J Rheumatol. 
1975;4(4):193-6. 
24. Hakim AJ, Cherkas LF, Spector TD, MacGregor AJ. Genetic associations between frozen 
shoulder and tennis elbow: a female twin study. Rheumatology (Oxford). 2003;42(6):739-42. 
25. Smith SP, Devaraj VS, Bunker TD. The association between frozen shoulder and Dupuytren's 
disease. J Shoulder Elbow Surg. 2001;10(2):149-51. 
26. Shah N, Lewis M. Shoulder adhesive capsulitis: systematic review of randomised trials using 
multiple corticosteroid injections. Br J Gen Pract. 2007;57(541):662-7. 
27. Chakravarty K, Webley M. Shoulder joint movement and its relationship to disability in the 
elderly. J Rheumatol. 1993;20(8):1359-61. 
28. Jost B, Koch PP, Gerber C. Anatomy and functional aspects of the rotator interval. J Shoulder 
Elbow Surg. 2000;9(4):336-41. 
29. Mengiardi B, Pfirrmann CW, Gerber C, Hodler J, Zanetti M. Frozen shoulder: MR arthrographic 
findings. Radiology. 2004;233(2):486-92. 
30. Ozaki J, Nakagawa Y, Sakurai G, Tamai S. Recalcitrant chronic adhesive capsulitis of the 
shoulder. Role of contracture of the coracohumeral ligament and rotator interval in 
pathogenesis and treatment. J Bone Joint Surg Am. 1989;71(10):1511-5. 
31. Kanbe K, Inoue K, Inoue Y, Chen Q. Inducement of mitogen-activated protein kinases in frozen 
shoulders. J Orthop Sci. 2009;14(1):56-61. 
32. Hand GCR, Athanasou NA, Matthews T, Carr AJ. The pathology of frozen shoulder. J Bone Joint 
Surg Br. 2007;89-B(7):928-32. 
33. Bunker TD, Reilly J, Baird KS, Hamblen DL. Expression of growth factors, cytokines and matrix 
metalloproteinases in frozen shoulder. J Bone Joint Surg Br. 2000;82-B(5):768-73. 
34. Rodeo SA, Hannafin JA, Tom J, Warren RF, Wickiewicz TL. Immunolocalization of cytokines and 
their receptors in adhesive capsulitis of the shoulder. J Orthop Res. 1997;15(3):427-36. 
35. Muller LP, Rittmeister M, John J, Happ J, Kerschbaumer F. Frozen shoulder--an 
algoneurodystrophic process? Acta Orthop Belg. 1998;64(4):434-40. 
36. Wassef MR. Suprascapular nerve block. A new approach for the management of frozen 
shoulder. Anaesthesia. 1992;47(2):120-4. 
37. Neviaser RJ, Neviaser TJ. The frozen shoulder. Diagnosis and management. Clin Orthop Relat 
Res. 1987(223):59-64. 
38. Grey RG. The natural history of "idiopathic" frozen shoulder. J Bone Joint Surg Am. 
1978;60(4):564. 





40. Binder AI, Bulgen DY, Hazleman BL, Roberts S. Frozen shoulder: a long-term prospective study. 
Ann Rheum Dis. 1984;43(3):361-4. 
41. Vastamäki HMD, Kettunen JPTP, Vastamäki MMDP. The Natural History of Idiopathic Frozen 
Shoulder: A 2- to 27-year Followup Study. Clin Orthop Relat Res. 2012;470(4):1133-43. 
42. Muir SW, Corea CL, Beaupre L. Evaluating change in clinical status: reliability and measures of 
agreement for the assessment of glenohumeral range of motion. N Am J Sports Phys Ther. 
2010;5:98-110. 
43. van der Windt DA, van der Heijden GJ, Scholten RJ, Koes BW, Bouter LM. The efficacy of non-
steroidal anti-inflammatory drugs (NSAIDS) for shoulder complaints. A systematic review. J Clin 
Epidemiol. 1995;48:691-704. 
44. Green S, Buchbinder R, Glazier R, Forbes A. Interventions for shoulder pain. Cochrane Database 
Syst Rev. 2000:CD001156. 
45. van der Heijden GJ, van der Windt DA, Kleijnen J, Koes BW, Bouter LM. Steroid injections for 
shoulder disorders: a systematic review of randomized clinical trials. Br J Gen Pract. 
1996;46:309-16. 
46. Brue S, Valentin A, Forssblad M, Werner S, Mikkelsen C, Cerulli G. Idiopathic adhesive capsulitis 
of the shoulder: a review. Knee Surg Sports Traumatol Arthrosc. 2007;15(8):1048-54. 
47. Leppala J, Kannus P, Sievanen H, Jarvinen M, Vuori I. Adhesive capsulitis of the shoulder (frozen 
shoulder) produces bone loss in the affected humerus, but long-term bony recovery is good. 
Bone. 1998;22(6):691-4. 
48. Cyriax J, Cyriax P. Illustrated manual of orthopaedic medicine. 2. ed. Oxford: Butterworth 
Heinemann; 1993. 
49. Lefevre-Colau MM, Drape JL, Fayad F, Rannou F, Diche T, Minvielle F, et al. Magnetic resonance 
imaging of shoulders with idiopathic adhesive capsulitis: reliability of measures. Eur Radiol. 
2005;15(12):2415-22. 
50. Rookmoneea M, Dennis L, Brealey S, Rangan A, White B, McDaid C, et al. The effectiveness of 
interventions in the management of patients with primary frozen shoulder. J Bone Joint Surg 
Br. 2010;92-B(9):1267-72. 
51. Klinger H-M, Otte S, Baums MH, Haerer T. Early arthroscopic release in refractory shoulder 
stiffness. Arch Orthop Trauma Surg. 2002;122(4):200-3. 
52. Itoi E, Arce G, Bain GI, Diercks RL, Guttmann D, Imhoff AB, et al. Shoulder Stiffness: Current 
Concepts and Concerns. Arthroscopy: The Journal of Arthroscopic & Related Surgery. 
2016;32(7):1402-14. 
53. Page MJ, Green S, Kramer S, Johnston RV, McBain B, Chau M, et al. Manual therapy and 
exercise for adhesive capsulitis (frozen shoulder). Cochrane Database of Systematic Reviews. 
2014(8). 
54. Vermeulen HM, Rozing PM, Obermann WR, le Cessie S, Vliet Vlieland TP. Comparison of high-
grade and low-grade mobilization techniques in the management of adhesive capsulitis of the 
shoulder: randomized controlled trial. Phys Ther. 2006;86(3):355-68. 
55. Diercks RL, Stevens M. Gentle thawing of the frozen shoulder: a prospective study of 
supervised neglect versus intensive physical therapy in seventy-seven patients with frozen 




56. Jewell DV, Riddle DL, Thacker LR. Interventions associated with an increased or decreased 
likelihood of pain reduction and improved function in patients with adhesive capsulitis: a 
retrospective cohort study. Phys Ther. 2009;89(5):419-29. 
57. Leung MS, Cheing GL. Effects of deep and superficial heating in the management of frozen 
shoulder. J Rehabil Med. 2008;40(2):145-50. 
58. Stergioulas A. Low-power laser treatment in patients with frozen shoulder: preliminary results. 
Photomed Laser Surg. 2008;26(2):99-105. 
59. Griggs SM, Ahn A, Green A. Idiopathic adhesive capsulitis. A prospective functional outcome 
study of nonoperative treatment. J Bone Joint Surg Am. 2000;82-A(10):1398-407. 
60. Melzer C, Wallny T, Wirth CJ, Hoffmann S. Frozen shoulder--treatment and results. Arch Orthop 
Trauma Surg. 1995;114(2):87-91. 
61. Sun Y, Lu S, Zhang P, Wang Z, Chen J. Steroid Injection Versus Physiotherapy for Patients With 
Adhesive Capsulitis of the Shoulder: A PRIMSA Systematic Review and Meta-Analysis of 
Randomized Controlled Trials. Medicine. 2016;95(20):e3469. 
62. Struyf F, Meeus M. Current evidence on physical therapy in patients with adhesive capsulitis: 
what are we missing? Clin Rheumatol. 2014;33(5):593-600. 
63. Binder A, Hazleman BL, Parr G, Roberts S. A controlled study of oral prednisolone in frozen 
shoulder. Br J Rheumatol. 1986;25(3):288-92. 
64. Buchbinder R, Hoving JL, Green S, Hall S, Forbes A, Nash P. Short course prednisolone for 
adhesive capsulitis (frozen shoulder or stiff painful shoulder): a randomised, double blind, 
placebo controlled trial. Ann Rheum Dis. 2004;63(11):1460-9. 
65. Buchbinder R, Green S, Youd JM, Johnston RV. Oral steroids for adhesive capsulitis. Cochrane 
Database Syst Rev. 2006(4):CD006189. 
66. Carette S, Moffet H, Tardif J, Bessette L, Morin F, Fremont P, et al. Intraarticular 
corticosteroids, supervised physiotherapy, or a combination of the two in the treatment of 
adhesive capsulitis of the shoulder: a placebo-controlled trial. Arthritis Rheum. 2003;48(3):829-
38. 
67. Bulgen DY, Binder AI, Hazleman BL, Dutton J, Roberts S. Frozen shoulder: prospective clinical 
study with an evaluation of three treatment regimens. Ann Rheum Dis. 1984;43(3):353-60. 
68. Ryans I, Montgomery A, Galway R, Kernohan WG, McKane R. A randomized controlled trial of 
intra-articular triamcinolone and/or physiotherapy in shoulder capsulitis. Rheumatology 
(Oxford). 2005;44(4):529-35. 
69. Maund E, Craig D, Suekarran S, Neilson A, Wright K, Brealey S, et al. Management of frozen 
shoulder: a systematic review and cost-effectiveness analysis. Health Technol Assess. 
2012;16(11):1-264. 
70. Blanchard V, Barr S, Cerisola FL. The effectiveness of corticosteroid injections compared with 
physiotherapeutic interventions for adhesive capsulitis: a systematic review. Physiotherapy. 
2010;96(2):95-107. 
71. Buchbinder R, Green S, Youd JM. Corticosteroid injections for shoulder pain. Cochrane 
Database Syst Rev. 2003(1):CD004016. 
72. Hegedus EJ, Zavala J, Kissenberth M, Cook C, Cassas K, Hawkins R, et al. Positive outcomes with 





73. Kraeutler MJ, Cohen SB, Ciccotti MG, Dodson CC. Accuracy of intra-articular injections of the 
glenohumeral joint through an anterior approach: arthroscopic correlation. J Shoulder Elbow 
Surg. 2012;21(3):380-3. 
74. Courtney P, Doherty M. Joint aspiration and injection and synovial fluid analysis. Best Practice 
& Research Clinical Rheumatology. 2013;27(2):137-69. 
75. Sethi PM, El Attrache N. Accuracy of Intra-articular Injection of the Glenohumeral Joint: A 
Cadaveric Study. Orthopedics. 2006;29(2):149-52. 
76. White AET, Tuite JD. The accuracy and efficacy of shoulder injections in restrictive capsulitis. 
Journal of Orthopaedic Rheumatology. 1996;9(1):37-40. 
77. Hollingworth GR, Ellis RM, Hattersley TS. Comparison of injection techniques for shoulder pain: 
results of a double blind, randomised study. Br Med J (Clin Res Ed). 1983;287(6402):1339-41. 
78. Eustace JA, Brophy DP, Gibney RP, Bresnihan B, FitzGerald O. Comparison of the accuracy of 
steroid placement with clinical outcome in patients with shoulder symptoms. Ann Rheum Dis. 
1997;56(1):59-63. 
79. Juel NG, Oland G, Kvalheim S, Løve T, Ekeberg OM. Adhesive capsulitis: one sonographic-
guided injection of 20 mg triamcinolon into the rotator interval. Rheumatol Int. 
2013;33(6):1547-53. 
80. Prestgaard T, Wormgoor ME, Haugen S, Harstad H, Mowinckel P, Brox JI. Ultrasound-guided 
intra-articular and rotator interval corticosteroid injections in adhesive capsulitis of the 
shoulder: a double-blind, sham-controlled randomized study. Pain. 2015;156(9):1683-91. 
81. Raeissadat SA, Rayegani SM, Langroudi TF, Khoiniha M. Comparing the accuracy and efficacy of 
ultrasound-guided versus blind injections of steroid in the glenohumeral joint in patients with 
shoulder adhesive capsulitis. Clin Rheumatol. 2017;36(4):933-40. 
82. Lee H-J, Lim K-B, Kim D-Y, Lee K-T. Randomized Controlled Trial for Efficacy of Intra-Articular 
Injection for Adhesive Capsulitis: Ultrasonography-Guided Versus Blind Technique. Arch Phys 
Med Rehabil. 2009;90(12):1997-2002. 
83. Bloom JE, Rischin A, Johnston RV, Buchbinder R. Image-guided versus blind glucocorticoid 
injection for shoulder pain. Cochrane Database of Systematic Reviews. 2012(8). 
84. de Jong BA, Dahmen R, Hogeweg JA, Marti RK. Intra-articular triamcinolone acetonide injection 
in patients with capsulitis of the shoulder: a comparative study of two dose regimens. Clin 
Rehabil. 1998;12(3):211-5. 
85. Yoon SH, Lee HY, Lee HJ, Kwack KS. Optimal Dose of Intra-articular Corticosteroids for Adhesive 
Capsulitis A Randomized, Triple-Blind, Placebo-Controlled Trial. Am J Sports Med. 
2013;41(5):1133-9. 
86. Williams NE, Seifert MH, Cuddigan JH, Wise RA. Treatment of capsulitis of the shoulder. 
Rheumatol Rehabil. 1975;14(4):236. 
87. Jacobs LG, Barton MA, Wallace WA, Ferrousis J, Dunn NA, Bossingham DH. Intra-articular 
distension and steroids in the management of capsulitis of the shoulder. BMJ. 
1991;302(6791):1498-501. 
88. Rizk TE, Pinals RS, Talaiver AS. Corticosteroid injections in adhesive capsulitis: investigation of 
their value and site. Arch Phys Med Rehabil. 1991;72(1):20-2. 
89. Winters JC, Sobel JS, Groenier KH, Arendzen HJ, Jong BM-d. Comparison of physiotherapy, 
manipulation, and corticosteroid injection for treating shoulder complaints in general practice: 




90. Gam AN, Schydlowsky P, Rossel I, Remvig L, Jensen EM. Treatment of "frozen shoulder" with 
distension and glucorticoid compared with glucorticoid alone. A randomised controlled trial. 
Scand J Rheumatol. 1998;27(6):425-30. 
91. van der Windt DA, Koes BW, Deville W, Boeke AJ, de Jong BA, Bouter LM. Effectiveness of 
corticosteroid injections versus physiotherapy for treatment of painful stiff shoulder in primary 
care: randomised trial. BMJ. 1998;317(7168):1292-6. 
92. Andren L, Lundberg BJ. Treatment of Rigid Shoulders by Joint Distension during Arthrography. 
Acta Orthop Scand. 1965;36:45-53. 
93. Vad VB, Sakalkale D, Warren RF. The role of capsular distention in adhesive capsulitis. Arch 
Phys Med Rehabil. 2003;84(9):1290-2. 
94. Fareed DO, Gallivan WR, Jr. Office management of frozen shoulder syndrome. Treatment with 
hydraulic distension under local anesthesia. Clin Orthop Relat Res. 1989(242):177-83. 
95. Bell S, Coghlan J, Richardson M. Hydrodilatation in the management of shoulder capsulitis. 
Australas Radiol. 2003;47(3):247-51. 
96. Quraishi NA, Johnston P, Bayer J, Crowe M, Chakrabarti AJ. Thawing the frozen shoulder. A 
randomised trial comparing manipulation under anaesthesia with hydrodilatation. J Bone Joint 
Surg Br. 2007;89(9):1197-200. 
97. Buchbinder R, Green S, Forbes A, Hall S, Lawler G. Arthrographic joint distension with saline 
and steroid improves function and reduces pain in patients with painful stiff shoulder: results 
of a randomised, double blind, placebo controlled trial. Ann Rheum Dis. 2004;63(3):302-9. 
98. Corbeil V, Dussault RG, Leduc BE, Fleury J. [Adhesive capsulitis of the shoulder: a comparative 
study of arthrography with intra-articular corticotherapy and with or without capsular 
distension]. Can Assoc Radiol J. 1992;43(2):127-30. 
99. Piotte F, Gravel D, Moffet H, Fliszar E, Roy A, Nadeau S, et al. Effects of repeated distension 
arthrographies combined with a home exercise program among adults with idiopathic adhesive 
capsulitis of the shoulder. Am J Phys Med Rehabil. 2004;83(7):537-46. 
100. Buchbinder R, Green S, Youd JM, Johnston RV, Cumpston M. Arthrographic distension for 
adhesive capsulitis (frozen shoulder). Cochrane Database Syst Rev. 2008(1):CD007005. 
101. Tveita EK, Tariq R, Sesseng S, Juel NG, Bautz-Holter E. Hydrodilatation, corticosteroids and 
adhesive capsulitis: a randomized controlled trial. BMC Musculoskelet Disord. 2008;9:53. 
102. Lin M-T, Hsiao M-Y, Tu Y-K, Wang T-G. Comparative Efficacy of Intra-Articular Steroid Injection 
and Distension in Patients With Frozen Shoulder: A Systematic Review and Network Meta-
Analysis. Arch Phys Med Rehabil. 2017. 
103. Wu W-T, Chang K-V, Han D-S, Chang C-H, Yang F-S, Lin C-P. Effectiveness of Glenohumeral Joint 
Dilatation for Treatment of Frozen Shoulder: A Systematic Review and Meta-analysis of 
Randomized Controlled Trials. Sci Rep. 2017;7(1):10507. 
104. Uppal HS, Evans JP, Smith C. Frozen shoulder: A systematic review of therapeutic options. 
World J Orthop. 2015;6(2):263-8. 
105. Ng CY, Amin AK, Narborough S, McMullan L, Cook R, Brenkel IJ. Manipulation under 
anaesthesia and early physiotherapy facilitate recovery of patients with frozen shoulder 
syndrome. Scott Med J. 2009;54(1):29-31. 
106. Wang JP, Huang TF, Hung SC, Ma HL, Wu JG, Chen TH. Comparison of idiopathic, post-trauma 





107. Farrell CM, Sperling JW, Cofield RH. Manipulation for frozen shoulder: Long-term results. J 
Shoulder Elbow Surg. 2005;14(5):480-4. 
108. Dodenhoff RM, Levy O, Wilson A, Copeland SA. Manipulation under anesthesia for primary 
frozen shoulder: effect on early recovery and return to activity. J Shoulder Elbow Surg. 
2000;9(1):23-6. 
109. Kivimäki J, Pohjolainen T, Malmivaara A, Kannisto M, Guillaume J, Seitsalo S, et al. 
Manipulation under anesthesia with home exercises versus home exercises alone in the 
treatment of frozen shoulder: A randomized, controlled trial with 125 patients. J Shoulder 
Elbow Surg. 2007;16(6):722-6. 
110. Iannotti JP. Manipulation under anesthesia did not enhance the benefit conferred by home 
exercises for frozen shoulder. J Bone Joint Surg Am. 2008;90(8):1792. 
111. Kivimäki J, Pohjolainen T. Manipulation under anesthesia for frozen shoulder with and without 
steroid injection. Arch Phys Med Rehabil. 2001;82(9):1188-90. 
112. Loew M, Heichel TO, Lehner B. Intraarticular lesions in primary frozen shoulder after 
manipulation under general anesthesia. J Shoulder Elbow Surg. 2005;14(1):16-21. 
113. Elhassan B, Ozbaydar M, Massimini D, Higgins L, Warner JJP. Arthroscopic capsular release for 
refractory shoulder stiffness: A critical analysis of effectiveness in specific etiologies. J Shoulder 
Elbow Surg. 2010;19(4):580-7. 
114. Snow M, Boutros I, Funk L. Posterior arthroscopic capsular release in frozen shoulder. 
Arthroscopy. 2009;25(1):19-23. 
115. Cinar M, Akpinar S, Derincek A, Circi E, Uysal M. Comparison of arthroscopic capsular release in 
diabetic and idiopathic frozen shoulder patients. Arch Orthop Trauma Surg. 2010;130(3):401-6. 
116. Holloway GB, Schenk T, Williams GR, Ramsey ML, Iannotti JP. Arthroscopic capsular release for 
the treatment of refractory postoperative or post-fracture shoulder stiffness. J Bone Joint Surg 
Am. 2001;83-A(11):1682-7. 
117. Fernandes MR. Arthroscopic capsular release for refractory shoulder stiffness. Rev Assoc Med 
Bras (1992). 2013;59(4):347-53. 
118. Dattani R, Ramasamy V, Parker R, Patel VR. Improvement in quality of life after arthroscopic 
capsular release for contracture of the shoulder. Bone Joint J. 2013;95-B(7):942-6. 
119. Grant JA, Schroeder N, Miller BS, Carpenter JE. Comparison of manipulation and arthroscopic 
capsular release for adhesive capsulitis: a systematic review. J Shoulder Elbow Surg. 
2013;22(8):1135-45. 
120. Harris AH, Youd J, Buchbinder R. A comparison of directly elicited and pre-scored preference-
based measures of quality of life: the case of adhesive capsulitis. Qual Life Res. 
2013;22(10):2963-71. 
121. Gartsman GM, Brinker MR, Khan M, Karahan M. Self-assessment of general health status in 
patients with five common shoulder conditions. J Shoulder Elbow Surg. 1998;7(3):228-37. 
122. Boorman RS, Kopjar B, Fehringer E, Churchill RS, Smith K, Matsen Iii FA. The effect of total 
shoulder arthroplasty on self-assessed health status is comparable to that of total hip 
arthroplasty and coronary artery bypassgrafting. J Shoulder Elbow Surg. 2003;12(2):158-63. 
123. Bruls VE, Bastiaenen CH, de Bie RA. Prognostic factors of complaints of arm, neck, and/or 




124. Williams JW, Jr., Holleman DR, Jr., Simel DL. Measuring shoulder function with the Shoulder 
Pain and Disability Index. J Rheumatol. 1995;22(4):727-32. 
125. Struyf F, Geraets J, Noten S, Meeus M, Nijs J. A Multivariable Prediction Model for the 
Chronification of Non-traumatic Shoulder Pain: A Systematic Review. Pain Physician. 
2016;19(2):1-10. 
126. Kuijpers T, van der Windt DA, Boeke AJ, Twisk JW, Vergouwe Y, Bouter LM, et al. Clinical 
prediction rules for the prognosis of shoulder pain in general practice. Pain. 2006;120(3):276-
85. 
127. Wylie JD, Suter T, Potter MQ, Granger EK, Tashjian RZ. Mental Health Has a Stronger 
Association with Patient-Reported Shoulder Pain and Function Than Tear Size in Patients with 
Full-Thickness Rotator Cuff Tears. JBJS. 2016;98(4):251-6. 
128. Baums MH, Spahn G, Nozaki M, Steckel H, Schultz W, Klinger H-M. Functional outcome and 
general health status in patients after arthroscopic release in adhesive capsulitis. Knee Surg 
Sports Traumatol Arthrosc. 2007;15(5):638-44. 
129. Harryman DT, 2nd, Matsen FA, 3rd, Sidles JA. Arthroscopic management of refractory shoulder 
stiffness. Arthroscopy. 1997;13(2):133-47. 
130. Anderson RT, Aaronson NK, Wilkin D. Critical review of the international assessments of health-
related quality of life. Qual Life Res. 1993;2(6):369-95. 
131. Eriksen HR, Ihlebæk C, Ursin H. A scoring system for subjective health complaints (SHC). 
Scandinavian Journal of Public Health. 1999;27(1):63-72. 
132. Barsky AJ, Borus JF. Functional somatic syndromes. Ann Intern Med. 1999;130(11):910-21. 
133. Rokstad K, Straand J, Sandvik H. [Patient encounters in general practice. An epidemiological 
survey in More and Romsdal]. Tidsskr Nor Laegeforen. 1997;117(5):659-64. 
134. Ihlebaek C, Eriksen HR, Ursin H. Prevalence of subjective health complaints (SHC) in Norway. 
Scand J Public Health. 2002;30(1):20-9. 
135. Bot SD, van der Waal JM, Terwee CB, van der Windt DA, Scholten RJ, Bouter LM, et al. 
Predictors of outcome in neck and shoulder symptoms: a cohort study in general practice. 
Spine (Phila Pa 1976). 2005;30(16):E459-70. 
136. Bongers PM, de Winter CR, Kompier MA, Hildebrandt VH. Psychosocial factors at work and 
musculoskeletal disease. Scand J Work Environ Health. 1993;19(5):297-312. 
137. Huang GD, Feuerstein M, Sauter SL. Occupational stress and work-related upper extremity 
disorders: concepts and models. Am J Ind Med. 2002;41(5):298-314. 
138. Kvale A, Ellertsen B, Skouen JS. Relationships between physical findings (GPE-78) and 
psychological profiles (MMPI-2) in patients with long-lasting musculoskeletal pain. Nord J 
Psychiatry. 2001;55(3):177-84. 
139. Turner JA, Jensen MP, Romano JM. Do beliefs, coping, and catastrophizing independently 
predict functioning in patients with chronic pain? Pain. 2000;85(1-2):115-25. 
140. Vlaeyen JW, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain: a 
state of the art. Pain. 2000;85(3):317-32. 
141. Watson D. Neuroticism A2 - Smelser, Neil J. In: Baltes PB, editor. International Encyclopedia of 
the Social & Behavioral Sciences. Oxford: Pergamon; 2001. p. 10609-12. 
142. Ombregt L, Bisschop P, ter Veer HJ. A System of Orthopaedic Medicine. 3rd ed. London: 




143. Green S, Buchbinder R, Forbes A, Bellamy N. A standardized protocol for measurement of 
range of movement of the shoulder using the Plurimeter-V inclinometer and assessment of its 
intrarater and interrater reliability. Arthritis Care Res. 1998;11:43-52. 
144. Watson L, Balster SM, Finch C, Dalziel R. Measurement of scapula upward rotation: a reliable 
clinical procedure. Br J Sports Med. 2005;39:599-603. 
145. Ginn KA, Cohen ML, Herbert RD. Does hand-behind-back range of motion accurately reflect 
shoulder internal rotation? J Shoulder Elbow Surg. 2006;15:311-4. 
146. Wakabayashi I, Itoi E, Minagawa H, Kobayashi M, Seki N, Shimada Y, et al. Does reaching the 
back reflect the actual internal rotation of the shoulder? J Shoulder Elbow Surg. 2006;15:306-
10. 
147. Breckenridge JD, McAuley JH. Shoulder Pain and Disability Index (SPADI). J Physiother. 
2011;57(3):197. 
148. Beaton DE, Richards RR. Measuring function of the shoulder. A cross-sectional comparison of 
five questionnaires. J Bone Joint Surg Am. 1996;78(6):882-90. 
149. MacDermid JC, Solomon P, Prkachin K. The Shoulder Pain and Disability Index demonstrates 
factor, construct and longitudinal validity. BMC Musculoskelet Disord. 2006;7:12-. 
150. Ekeberg OM, Bautz-Holter E, Tveitå EK, Keller A, Juel NG, Brox JI. Agreement, reliability and 
validity in 3 shoulder questionnaires in patients with rotator cuff disease. BMC Musculoskelet 
Disord. 2008;9:68-. 
151. Staples MP, Forbes A, Green S, Buchbinder R. Shoulder-specific disability measures showed 
acceptable construct validity and responsiveness. J Clin Epidemiol. 2010;63(2):163-70. 
152. Tveita EK, Sandvik L, Ekeberg OM, Juel NG, Bautz-Holter E. Factor structure of the Shoulder 
Pain and Disability Index in patients with adhesive capsulitis. BMC Musculoskelet Disord. 
2008;9:103. 
153. Tveita EK, Ekeberg OM, Juel NG, Bautz-Holter E. Responsiveness of the shoulder pain and 
disability index in patients with adhesive capsulitis. BMC Musculoskelet Disord. 2008;9:161. 
154. Roy J-S, MacDermid JC, Woodhouse LJ. Measuring shoulder function: A systematic review of 
four questionnaires. Arthritis Care Res. 2009;61(5):623-32. 
155. Hill CL, Lester S, Taylor AW, Shanahan ME, Gill TK. Factor structure and validity of the shoulder 
pain and disability index in a population-based study of people with shoulder symptoms. BMC 
Musculoskelet Disord. 2011;12:8-. 
156. Paul A, Lewis M, Shadforth M, Croft P, van der Windt DAWM, Hay E. A comparison of four 
shoulder-specific questionnaires in primary care. Ann Rheum Dis. 2004;63(10):1293-9. 
157. Bot S, Terwee C, van der Windt DAWM, Bouter L, Dekker J, de Vet HCW. Clinimetric evaluation 
of shoulder disability questionnaires: a systematic review of the literature. Ann Rheum Dis. 
2004;63(4):335-41. 
158. Angst F, Goldhahn J, Pap G, Mannion AF, Roach KE, Siebertz D, et al. Cross-cultural adaptation, 
reliability and validity of the German Shoulder Pain and Disability Index (SPADI). Rheumatology 
(Oxford). 2007;46(1):87-92. 
159. Schmitt JS, Di Fabio RP. Reliable change and minimum important difference (MID) proportions 





160. Hartrick CT, Kovan JP, Shapiro S. The numeric rating scale for clinical pain measurement: a ratio 
measure? Pain Pract. 2003;3. 
161. Lara-Munoz C, De Leon SP, Feinstein AR, Puente A, Wells CK. Comparison of three rating scales 
for measuring subjective phenomena in clinical research. I. Use of experimentally controlled 
auditory stimuli. Arch Med Res. 2004;35. 
162. Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, et al. Studies comparing 
Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of 
pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 
2011;41(6):1073-93. 
163. Breivik EK, Bjornsson GA, Skovlund E. A comparison of pain rating scales by sampling from 
clinical trial data. Clin J Pain. 2000;16(1):22-8. 
164. Brunelli C, Zecca E, Martini C, Campa T, Fagnoni E, Bagnasco M, et al. Comparison of numerical 
and verbal rating scales to measure pain exacerbations in patients with chronic cancer pain. 
Health and Quality of Life Outcomes. 2010;8(1):42. 
165. Eysenck HJ. A short questionnaire for the measurement of two dimensions of personality. J 
Appl Psychol. 1958;42(1):14-7. 
166. Riddle DL, Rothstein JM, Lamb RL. Goniometric Reliability in a Clinical Setting: Shoulder 
Measurements. Phys Ther. 1987;67:668-73. 
167. MacDermid JC, Chesworth BM, Patterson S, Roth JH. Intratester and intertester reliability of 
goniometric measurement of passive lateral shoulder rotation. J Hand Ther. 1999;12:187-92. 
168. Hayes K, Walton JR, Szomor ZR, Murrell GA. Reliability of five methods for assessing shoulder 
range of motion. Aust J Physiother. 2001;47:289-94. 
169. Kolber MJ, Hanney WJ. The reliability, minimal detectable change and construct validity of a 
clinical measurement for identifying posterior shoulder tightness. N Am J Sports Phys Ther. 
2010;5:208-19. 
170. Nadeau S, Kovacs S, Gravel D, Piotte F, Moffet H, Gagnon D, et al. Active movement 
measurements of the shoulder girdle in healthy subjects with goniometer and tape measure 
techniques: a study on reliability and validity. Physiother Theory Pract. 2007;23:179-87. 
171. Hoving JL, Buchbinder R, Green S, Forbes A, Bellamy N, Brand C, et al. How reliably do 
rheumatologists measure shoulder movement? Ann Rheum Dis. 2002;61:612-6. 
172. Croft P, Pope D, Boswell R, Rigby A, Silman A. Observer variability in measuring elevation and 
external rotation of the shoulder. Primary Care Rheumatology Society Shoulder Study Group. 
Br J Rheumatol. 1994;33:942-6. 
173. Mullaney MJ, McHugh MP, Johnson CP, Tyler TF. Reliability of shoulder range of motion 
comparing a goniometer to a digital level. Physiother Theory Pract. 2010;26:327-33. 
174. Kolber MJ, Vega F, Widmayer K, Cheng MS. The reliability and minimal detectable change of 
shoulder mobility measurements using a digital inclinometer. Physiother Theory Pract. 
2011;27:176-84. 
175. de Vet HCW, Terwee CB, Mokkink LB, Knol DL. Measurements in Medicine Cambridge: 
Cambridge University Press; 2011. 338 p. 
176. Giraudeau B, Mary JY. Planning a reproducibility study: how many subjects and how many 
replicates per subject for an expected width of the 95 per cent confidence interval of the 




177. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med 
Res. 1999;8(2):135-60. 
178. Eysenck SBG, Eysenck HJ, Barrett P. A revised version of the psychoticism scale. Pers Individ Dif. 
1985;6(1):21-9. 
179. Francis LJ, Brown LB, Philipchalk R. The development of an abbreviated form of the revised 
Eysenck personality questionnaire (EPQR-A): Its use among students in England, Canada, the 
U.S.A. and Australia. Pers Individ Dif. 1992;13(4):443-9. 
180. Eliasziw M, Young SL, Woodbury MG, Fryday-Field K. Statistical methodology for the 
concurrent assessment of interrater and intrarater reliability: using goniometric measurements 
as an example. Phys Ther. 1994;74:777-88. 
181. Carter EC, Lubinsky J. Rehabilitation Research. Principles and Applications. 4th ed. St. Louis: 
Elsevier Saunders; 2011. 503 p. 
182. Norman GR, Streiner DL. Biostatistics, the Bare Essentials (4th Edition) Shelton, CT, USA: 
People's Medical Publishing House; 2014. 
183. Abraha I, Cherubini A, Cozzolino F, De Florio R, Luchetta ML, Rimland JM, et al. Deviation from 
intention to treat analysis in randomised trials and treatment effect estimates: meta-
epidemiological study. BMJ. 2015;350:h2445. 
184. Lewis JA, Machin D. Intention to treat--who should use ITT? Br J Cancer. 1993;68(4):647-50. 
185. Pannucci CJ, Wilkins EG. Identifying and Avoiding Bias in Research. Plast Reconstr Surg. 
2010;126(2):619-25. 
186. Hsu JE, Anakwenze OA, Warrender WJ, Abboud JA. Current review of adhesive capsulitis. J 
Shoulder Elbow Surg. 2011;20(3):502-14. 
187. Neviaser AS, Hannafin JA. Adhesive Capsulitis. The American Journal of Sports Medicine. 
2010;38(11):2346-56. 
188. Davis RE, Couper MP, Janz NK, Caldwell CH, Resnicow K. Interviewer effects in public health 
surveys. Health Educ Res. 2010;25(1):14-26. 
189. Godwin M, Ruhland L, Casson I, MacDonald S, Delva D, Birtwhistle R, et al. Pragmatic controlled 
clinical trials in primary care: the struggle between external and internal validity. BMC Med Res 
Methodol. 2003;3(1):28. 
190. Tasto JP, Elias DW. Adhesive capsulitis. Sports Med Arthrosc. 2007;15(4):216-21. 
191. Wang K, Ho V, Hunter-Smith DJ, Beh PS, Smith KM, Weber AB. Risk factors in idiopathic 
adhesive capsulitis: a case control study. J Shoulder Elbow Surg. 2013;22(7):e24-e9. 
192. Balci N, Balci MK, Tuzuner S. Shoulder adhesive capsulitis and shoulder range of motion in type 
II diabetes mellitus: association with diabetic complications. J Diabetes Complications. 
1999;13(3):135-40. 
193. Moren-Hybbinette I, Moritz U, Schersten B. The clinical picture of the painful diabetic shoulder-
-natural history, social consequences and analysis of concomitant hand syndrome. Acta Med 
Scand. 1987;221(1):73-82. 
194. Pringle M, Churchill R. Randomised controlled trials in general practice. BMJ. 
1995;311(7017):1382-3. 
195. Lee HJ, Lim KB, Kim DY, Lee KT. Randomized controlled trial for efficacy of intra-articular 
injection for adhesive capsulitis: ultrasonography-guided versus blind technique. Arch Phys 




196. Song A, Higgins LD, Newman J, Jain NB. Glenohumeral corticosteroid injections in adhesive 
capsulitis: a systematic search and review. PM & R : the journal of injury, function, and 
rehabilitation. 2014;6(12):1143-56. 
197. Yoon S-H, Lee HY, Lee HJ, Kwack K-S. Optimal Dose of Intra-articular Corticosteroids for 
Adhesive Capsulitis: A Randomized, Triple-Blind, Placebo-Controlled Trial. The American 
Journal of Sports Medicine. 2013;41(5):1133-9. 
198. Kim Y-S, Lee H-J, Lee D-H, Choi K-Y. Comparison of high- and low-dose intra-articular 
triamcinolone acetonide injection for treatment of primary shoulder stiffness: a prospective 
randomized trial. J Shoulder Elbow Surg. 2017;26(2):209-15. 
199. Winters JC, Sobel JS, Groenier KH, Arendzen HJ, Meyboom-de Jong B. Comparison of 
physiotherapy, manipulation, and corticosteroid injection for treating shoulder complaints in 
general practice: randomised, single blind study. 1997. p. 1320-. 
200. de Winter AF, Heemskerk MA, Terwee CB, Jans MP, Deville W, van Schaardenburg DJ, et al. 
Inter-observer reproducibility of measurements of range of motion in patients with shoulder 
pain using a digital inclinometer. BMC Musculoskelet Disord. 2004;5:18. 
201. Gajdosik RL, Bohannon RW. Clinical Measurement of Range of Motion: Review of Goniometry 
Emphasizing Reliability and Validity. Phys Ther. 1987;67:1867-72. 
202. Buchbinder R, Youd JM, Green S, Stein A, Forbes A, Harris A, et al. Efficacy and cost-
effectiveness of physiotherapy following glenohumeral joint distension for adhesive capsulitis: 
a randomized trial. Arthritis Rheum. 2007;57(6):1027-37. 
203. Sun Y, Zhang P, Liu S, Li H, Jiang J, Chen S, et al. Intra-articular Steroid Injection for Frozen 
Shoulder: A Systematic Review and Meta-analysis of Randomized Controlled Trials With Trial 
Sequential Analysis. The American Journal of Sports Medicine. 2017;45(9):2171-9. 
204. Saunders S, Longworth S. Injection Techniques in Musculoskeletal Medicine. 4th ed. London: 
Churchill Livingstone, Elsevier; 2011 19.10.2011. 268 p. 
205. Kinge JM, Sælensminde K, Dieleman J, Vollset SE, Norheim OF. Economic losses and burden of 
disease by medical conditions in Norway. Health Policy. 2017;121(6):691-8. 
206. van den Hout WB, Vermeulen HM, Rozing PM, Vliet Vlieland TPM. Impact of adhesive capsulitis 
and economic evaluation of high-grade and low-grade mobilisation techniques. Aust J 
Physiother. 2005;51(3):141-9. 
207. Bagheri F, Ebrahimzadeh MH, Moradi A, Bidgoli HF. Factors Associated with Pain, Disability and 
Quality of Life in Patients Suffering from Frozen Shoulder. Archives of Bone and Joint Surgery. 
2016;4(3):243-7. 
208. Ding H, Tang Y, Xue Y, Yang Z, Li Z, He D, et al. A report on the prevalence of depression and 
anxiety in patients with frozen shoulder and their relations to disease status. Psychol Health 
Med. 2014;19(6):730-7. 
209. Engebretsen K, Grotle M, Bautz-Holter E, Ekeberg OM, Brox JI. Predictors of shoulder pain and 
disability index (SPADI) and work status after 1 year in patients with subacromial shoulder pain. 
BMC Musculoskelet Disord. 2010;11. 
210. Ursin H, Endresen IM, Ursin G. Psychological factors and self-reports of muscle pain. Eur J Appl 
Physiol Occup Physiol. 1988;57(3):282-90. 
211. Ring D, Kadzielski J, Fabian L, Zurakowski D, Malhotra LR, Jupiter JB. Self-reported upper 




212. Pekarek B, Osher L, Buck S, Bowen M. Intra-articular corticosteroid injections: A critical 
literature review with up-to-date findings. The Foot. 2011;21(2):66-70. 
213. Caldwell JR. Intra-articular corticosteroids. Guide to selection and indications for use. Drugs. 
1996;52(4):507-14. 


































RESEARCH ARTICLE Open Access
Passive range of motion in patients with adhesive
shoulder capsulitis, an intertester reliability study
over eight weeks
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Abstract
Background: Measuring range of motion (ROM) in the shoulder joint is important for the diagnosis and monitoring
of change over time. To what degree passive ROM can be trusted as a reliable outcome measure was examined as
part of an on-going randomized controlled trial for patients with shoulder capsulitis. The aim of this study was to
examine intertester reliability of passive ROM in the shoulder joint over a period of eight weeks in patients with
adhesive capsulitis stage II.
Methods: Fifty patients with a clinical diagnosis of adhesive shoulder capsulitis were examined by two independent
testers. A predefined protocol was used for measuring passive range of motion with an inclinometer, a plurimeter, in
both affected and non-affected shoulders three times; at the start of the study and after 4 and 8 weeks.
Results: Very good to excellent intertester agreements were found for most parameters for the affected arm at all
three test points. The intraclass correlation coefficient (ICC 2.1) values ranged from 0.76 to 0.98, i.e. from very reliable to
excellent. The measurement error was in general small for the affected arm (5°–7°). ICCs were slightly lower for the
non-affected arm at 8 weeks, but with acceptable measurement errors.
Conclusions: Intertester reliability between two testers was very good at three visits over a time period of eight weeks
using a plurimeter to measure passive range of motion in patients with adhesive shoulder capsulitis. This method can
reliably determine passive range of motion in this patient population and be a reliable outcome measure.
Keywords: Adhesive capsulitis, Reliability, Passive range of motion, Plurimeter
Background
Range of motion (ROM) in the shoulder joint is among
the commonly used clinical criteria for diagnostic pur-
poses and to monitor effectiveness of given treatment
[1]. ROM is often used as an outcome measure in stud-
ies observing effect of intervention in stiff joints and in
shoulder pain [2-4]. Therefore it is important that the
movement measured is reproducible without much vari-
ation, independent of instrument being used.
Shoulder capsulitis is a painful condition affecting be-
tween 2 - 5% of the adult population [5-7]. There is a
global reduction of active and passive movement, generally
in a capsular pattern characterized by most reduction of
external rotation, less of abduction and least of internal ro-
tation. Reliable measurement of ROM is therefore essen-
tial for the correct diagnosis of adhesive capsulitis of the
shoulder, as this is mainly a clinical diagnosis. Measure-
ment variations in patients with shoulder capsulitis are
bound to occur due to pain, fear of pain, stiffness, fatigue
and measurement error at any one given time point [1].
To our knowledge no intertester reliability study has been
conducted in this patient group. Reliability of measure-
ments is therefore essential on both the affected and the
non-affected side for diagnostic purposes and over time to
monitor progression. Earlier intertester reliability studies
have usually measured only affected [8-10] or only non-
affected shoulders [11,12] and with participant numbers
below 35, and ROM has only been measured at one visit
or with an insignificant time difference between measure-
ments [8,10-15]. Most former studies have only reported
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correlation coefficients and have not reported standard
error of measurement (sw) [8,14,16,17]. Although as many
as 50 patients have recently been recommended to be in-
cluded in reliability studies (p. 126 in de Vet et al., [18]),
only a few studies have examined this many participants
[8,17,19,20]. See Table 1 for an overview of former studies.
To what degree ROM can be trusted as a reliable out-
come measure was examined as part of an on-going ran-
domized controlled trial for patients with adhesive
capsulitis of the shoulder. The aims of the study were:
 To determine the reliability of shoulder passive
ROM (PROM) bilaterally between two testers in a
large number of participants with adhesive capsulitis
using a validated measuring instrument, the
plurimeter [16,25], over an eight week period.
 To determine if the measurement error remained
the same during the eight week period, measured
three times four weeks apart.
The intertester reliability was evaluated for PROM in
abduction, external rotation, internal rotation and “hand
behind back” in patients with shoulder capsulitis.
Methods
PROM in the shoulder joint is defined as to the extent
an investigator can move the arm until pain or stiffness
limits the movement. We measured PROM on both the
affected side and the non-affected side. There are no set
rules regarding measurement intervals or the number of
times measurement should take place. To avoid too
much pain provocation we decided to measure each
movement only once for each tester. Therefore a total of
eight measurements for PROM were carried out for each
of the two testers on each patient. No standardized time
interval was set between tester 1 and 2, and usually only
a few minutes elapsed between the two measurement
sessions.
Participants
Patients potentially eligible for inclusion in the random-
ized controlled trial for treatment of shoulder capsulitis
were referred to a primary care clinic by physicians and
physiotherapists in the period 2010–2012. The study
was approved by the Regional Ethical Committee REK
NORD, reference 148/2008, in compliance with the
Helsinki Declaration. Informed consent was obtained
from all participants, and from the tester appearing in
the photographs.
The measurement took place on the second consult-
ation and is hereafter referred to as visit 1 in the study.
The PROM testing took place on visit 1, four weeks later
(visit 2) and then at eight weeks (visit 3).
To be included in the study patients had to be above
18 years of age, should be able to understand and speak
Norwegian, and there should be no contraindications for
use of corticosteroids. Participants should have reduced
range of motion in a capsular pattern with a reduction
of more than 30% of two out of three shoulder move-
ments and none of the three movements (Abduction =
ABD, External rotation = ER and Internal rotation = IR)
should be normal. All patients were having both pain
and stiffness, and can be referred to as being in stage 1
and/or stage 2 [25,26]. Patients with diabetes, asthma,
pregnant women and breast feeding mothers were ex-
cluded from the study.
The first 50 participants recruited in the main study
were included in the intertester reliability study, com-
prising 22 men and 28 women, age ranging from 38 years
to 75 years (mean age 52 years; SD 9.3). Along with
other demographic data, information regarding the af-
fected shoulder, such as the side affected, how long the
condition had lasted and details of any previous treat-
ment, was collected before taking the PROM measure-
ments. Mean pain intensity measured with Numerical
Pain rating Scale (NPRS) was 6.8 (SD 1.7) and Shoulder
Pain and Disability Index (SPADI) was 63.0 (SD 19.3).
Four of the included participants had bilateral capsulitis.
In these patients we chose the more affected side as the
“affected” and the other side as the “non-affected” side.
Testers
Both testers were experienced general practitioners and
had experience with measurements of shoulder move-
ments with goniometer from a former pilot study. They
had also trained with plurimeter on each other and on
patients with shoulder capsulitis before the start of the
study. Tester 2 (SS), who is also a physiotherapist, had
experience in measurements of ROM. The testers planned
beforehand how the measurements were to be carried out
and standardised the procedures. The two testers per-
formed ROM-testing in the same order; tester 2 always
tested first and tester 1 last. The two testers kept their
measurements records confidential and inaccessible to
each other throughout the duration of the study until all
the data was collected.
Measurements
The Plurimeter-V gravity inclinometer (Plurimeter-V in-
clinometer; Dr. Rippstein, Zurich, Switzerland) was used
in this study to measure PROM for abduction, external
rotation and internal rotation. A plurimeter is a hand-
held instrument for measuring relative angles between
surfaces. In the gravity referenced inclinometer the start-
ing position for the measurement is fixed, which is either
0° or 180°. The reliability of this instrument for measur-
ing shoulder and scapular passive range of motion
Sharma et al. BMC Musculoskeletal Disorders  (2015) 16:37 Page 2 of 9
Table 1 Summary of intra- and intertester reliability studies for range of motion on both the affected and the non-affected
shoulders using different measuring modalities
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(PROM) has been examined in previous studies [16,27].
The exact technique of measurement was standardised
considering the position of the patient, position of the
arm in relation to the body, and position of the pluri-
meter in relation to the arm (Figure 1 a-d). The starting
position of the plurimeter was from 0 for every measure-
ment with the instrument on the arm prior to the start
of the shoulder movement. This minimizes placement
error. To determine the end point of range, the arm was
passively moved up to the tolerance level of pain or
Table 1 Summary of intra- and intertester reliability studies for range of motion on both the affected and the non-affected












































AROM: ER Non-affected 0.88
AROM: IR 0.93








PROM: ER Affected 0.94
ABD = abduction, ER = external rotation, IR = internal rotation, HBB = hand behind back, EL = elevation, PROM = Passive range of motion, AROM = Active range of
motion, Sw = standard error of measurement, scap. stab = scapular stabilization.
With few exceptions only the inter-tester ICC values are written in the table.
Figure 1 Measurement of passive range of motion in shoulder. a) Abduction. b) External rotation. c) Internal rotation. d) Hand behind back.
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when it was not possible to move it further due to
stiffness.
The following individual passive movements were
measured:
In standing
Passive gleno-humeral abduction (ABD) The patient
was in standing position and the tester stood partly be-
hind and partly to the side of the patient to be mea-
sured. The scapula was stabilized by the tester holding
the inferior angle of the scapula between thumb and
index finger of one hand and holding the patients arm
just proximal to the patient’s elbow while at the same
time holding the plurimeter between 2nd and 3rd finger
on the dorsal aspect of the upper arm. Care was taken
to hold the plurimeter base in a straight line on the
upper arm. The arm was then passively abducted. The
end point was reached either when the pain was re-
ported as unbearable by the patient or the scapula began
to rotate and the examiner could not hold the scapula in
place. The reading on the plurimeter was then registered.
Hand behind back (HBB) HBB was measured in centi-
metres. The patient was in standing position and the dis-
tance was measured in centimetres (cm) by placing the
patient’s hand behind the back as far as it could reach
within pain limits with the ventral side of palm facing
outwards. The end point was considered to be the high-
est landmark reached with the upper end of the radius
proximal to the wrist. We chose the distal end of radius
as the highest landmark to avoid measurement errors in-
volving movement of wrist and thumb. The starting
point (0 point) was taken from the posterior inferior iliac
spine (PIIS). If the hand did not reach PIIS, the distance
to PIIS was denoted in minus centimeters (−cm). In case
the hand did not reach medially enough, parallel lines
were drawn from the 0 point and the distance between
them was measured horizontally. Though a complex
movement, this is a pragmatic way of measuring internal
rotation of the shoulder joint and is commonly used in
clinical situations [16]. Studies have however demon-
strated that HBB does not measure the exact range of
internal rotation [28,29].
In supine lying
Passive external rotation (ER) in 45° of abduction
The patient was lying supine with about 45° of gleno-
humeral abduction and the elbow was kept at 90° of
flexion and the forearm was kept in mid position. The
plurimeter was placed between the shaft of radius and
ulna in a straight line. The arm was rotated in external
rotation. If the arm did not reach 0°, the ROM was
noted in minus degrees.
Passive internal rotation (IR) in 45° of abduction The
position of the patient was the same as for measuring
ER. The arm was then rotated in internal rotation. The
reading on plurimeter was registered at the end point of
movement i.e. when the pain was unbearable or the arm
could not be moved further.
Statistics
Descriptive statistics with mean measurement including
standard deviation (SD) for each movement is presented.
Reliability refers to relative agreement as well as absolute
measurement error. For calculation of reliability the
Intraclass correlation coefficients (ICC model 2.1) was
used, as this accounts for both systematic and random
error. ICC is a reliability parameter and ranges between
0 and 1, and there are no fixed standards regarding what
can be considered as acceptable. According to Eliasziw
and co-workers [30], ICC values from 0.60 to 0.79 indi-
cate moderate reliability, values ≥0.80 to 0.90 as very re-
liable, and >0.90 as excellent. For absolute agreement,
which is the actual difference in measurements (i.e. ab-
solute measurement error in degrees and centimeters),
the size of measurement error was calculated. Bland and
Altman [31] have suggested estimating within-subject
standard deviation (sw), i.e. the common SD of repeated
measurements, derived from one-way analysis of vari-
ance. Statistical analysis was carried out using the IBM
SPSS Statistics version 19, software program.
Results
Mean raw data for measurement of abduction, external
and internal rotation and hand behind back are listed for
both the affected and the non-affected arm in Tables 2,
3, 4 and 5.
Table 2 Mean range and standard deviation (SD) for two
testers for abduction (ABD) in 50 patients with shoulder
capsulitis
Visit Tests ROM tester 1 ROM tester 2 ICC sw
ROM° (SD) ROM° (SD) 2,1 °
1. ABD non-affected 87.3 (7.7) 88.4 (6.6) 0.91 2.1
ABD affected 53.2 (17.0) 54.1 (15.1) 0.83 6.7
2. ABD non-affected 88.3 (6.8) 89.0 (4.7) 0.88 2.0
ABD affected 60.6 (17.9) 61.7 (18.7) 0.90 5.9
3. ABD non-affected 89.7 (2.9) 89.7 (1.6) 0.64 1.4
ABD affected 65.4 (19.5) 68.3 (19.5) 0.86 7.2
Relative agreement is reported with intraclass correlation coefficient, ICC (2.1),
and absolute measurement error is reported with within-subject standard deviation,
sw, between the two testers. ROM=Range of motion.
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Abduction (ABD)
Very good to excellent reliability calculated with ICC 2.1
was found during all three visits, except for the 3rd visit
for the normal side (Table 2).
The measurement error (sw) for the affected arm
ranged from 6.7° at first visit, 5.9° at the 2nd and 7.2° at
the last visit, whereas sw for the non-affected arm was
between 1.4 and 2.1°.
External rotation (ER)
Very good to excellent reliability was found at all three
visits, except for a moderate reliability shown for the
non-affected arm on the third visit (Table 3).
The measurement error (sw) for the affected arm ranged
between 4.5°, 5.8° and 6.2°. The sw was almost the same
for the healthy arm: 6.5° on the first visit and 5.7° on the
last.
Internal rotation (IR)
Good reliability calculated with ICCs was found on both
the normal and affected side for all three visits, except
for moderate reliability (ICC 0.63) shown in the last visit
for the normal arm. Measurement error for IR ranged
from 5.6° to 7.0° on the affected side and from to 5.1° to
6.2 on the healthy side (Table 4).
Hand behind back (HBB)
Excellent reliability was found on both the normal and
the affected side when measuring HBB. The measure-
ment error ranged from 1.6 cm to 1.9 cm on the affected
side, and from 1.1 cm to 2.1 cm on the normal side
(Table 5).
Graphic scatter plots showed that there were a few
outliers (see Figure 2a and b) where the two testers had
measured a difference in range of 15° - 20° in a couple
of patients.
Discussion
This large cohort study demonstrated very good to ex-
cellent intertester reliability when examining PROM in
patients with shoulder adhesive capsulitis stage II. The
results in our study are comparable or better than other
reliability studies measuring shoulder ROM in normal
individuals or in other shoulder populations (Table 1)
[8,13,16,17,20,22,24]. To our knowledge this is the first
reliability study that has measured passive ROM in pa-
tients with adhesive shoulder capsulitis using a pluri-
meter, whereas most former studies have used a variety
of measuring instruments and techniques. The intertes-
ter reliability remained excellent at all three visits for
examination of the affected side. The unaffected arm
had stable measurements over time, while the affected
arm changed over time, possibly due to treatment and/
or general improvement. The measurement errors were
found to vary between ~5°- 7° on all three visits when
examining the affected shoulder for passive abduction,
and bilaterally when examining external and internal ro-
tation. The measurement error was relatively small when
examining abduction (ABD) (~1.5°- 2°) in the normal
arm and for measuring hand behind back (HBB) in both
arms (~1 cm −2 cm) on all three visits. Some of the
good results found in our study may be attributed to
training of the testers who practiced the procedures on
each other and on patients before the start of the study.
Better results have been observed due to increased prac-
tice earlier [16].
The ICCs values for the affected side were very reliable
on all three visits (ICCs ≥ 0.83 - 0.96). The measure-
ments on the non-affected side had slightly lower ICC
values than the affected side, but only at the third visit.
De Winter et al. [17] had an ICC of 0.28 on the non-
affected side and 0.83 on the affected side for ABD, and
0.56 for the non-affected side and 0.90 for the affected
side for ER in patients with painful shoulder. Possibly a
combination of low spread in scores and low variance
has resulted in a low ICC, albeit with a low measure-
ment error as demonstrated in Figure 2 b.
The absolute measurement error found in our study
is generally better than the few studies where ROM in
the shoulder has been measured. However, no values
Table 3 Mean range and standard deviation (SD) for two
testers for external rotation (ER) in 50 patients with
shoulder capsulitis
Visit Tests ROM Tester 1 ROM Tester 2 ICC sw
ROM° (SD) ROM° (SD) 2,1 °
1. ER non-affected 70.8 (16.0) 75.0 (17.9) 0.83 6.5
ER affected 18.6 (16.2) 22.1 (16.1) 0.90 4.5
2. ER non-affected 71.8 (14.1) 76.4 (15.7) 0.80 6.0
ER affected 25.0 (19.2) 28.6 (17.6) 0.89 5.8
3. ER non-affected 72.0 (13.2) 78.5 (11.3) 0.69 5.7
ER affected 34.0 (22.6) 35.3 (19.2) 0.91 6.2
Table 4 Mean range and standard deviation (SD) for two
testers for internal rotation (IR) and hand behind back
(HBB) in 50 patients with shoulder capsulitis
Visit Tests ROM Tester 1 ROM Tester 2 ICC sw
ROM° (SD) ROM° (SD) 2,1 °
1. IR non-affected 73.0 (14.3) 77.9 (13.9) 0.76 6.2
IR affected 40.7 (14.9) 42.4 (14.1) 0.85 7
2. IR non-affected 72.9 (13.0) 78.0 (13.4) 0.78 5.4
IR affected 44.3 (16.9) 47.3 (17.8) 0.85 6.4
3. IR non-affected 73.8 (10.8) 80.3 (9.9) 0.63 5.1
IR affected 51.0 (18.3) 54.1 (18.0) 0.89 5.6
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have formerly been reported on patients with capsuli-
tis. Hayes et al. [10] found standard error of measure-
ment (i.e. sw) to range from 14° - 25° for flexion, ABD
and IR. Kolber et al. [11] reported small sw ranging
from approximately 2° - 4° in ABD, ER and IR among
30 normal participants. In the study by de Winter et al.
[17], 155 participants with shoulder pain were exam-
ined, and sw ranged from 14° - 20° for ABD and ER.
Muir et al. [1] studied a mixed participant group of 17,
and the sw ranged from 6° - 9° in flexion, ABD, ER and
IR in supine lying. The measurement error indicates
that some variation must be expected when using
ROM as an outcome measure. In our study the af-
fected arm had about 1/3 to ½ of the ROM as com-
pared to the non-affected arm at the first visit. Smallest
detectable change SDD (√2 x1.96 = 2.77 sw) is often used
to indicate statistical significant change [32]. An sw of
~5°–7° for ER, IR and ABD and an sw of ~2 cm for HBB
for the affected side would indicate that statistical change
larger than the measurement error in the effect study
would have to be 14°- 19°, and ~5.5 cm. In our study, the
SDD values for the affected arm were close to statistical
significant change above measurement error from the first
to the third visit. Range of motion is an important and re-
liable outcome measure, and a change of ≥15° is necessary
to represent a clinically significant change in patients with
adhesive capsulitis. Patients with shoulder capsulitis in
stage II generally have a large movement reduction and a
change of >15° has a positive impact on functionality in
activities of daily living. Clinically important change
should be defined within a context, and may sometimes
be smaller than the SDD [33].
A sample size of 50 participants and measurement
of ROM on both the affected and non-affected side
constitutes a large sample size for examination of reli-
ability [18]. Inclusion of 50 patients was based on the
recommendations made in “Measurement in medi-
cine” [32]. However, since two testers tested both sides
three times, a lower sample size would have been
sufficient.
Our sample is representative concerning gender (56%
female) and age (mean 52 years) for patients with
shoulder adhesive capsulitis in stage II [15]. At inclu-
sion, participants in our study were patients with mod-
erate to severe capsulitis. The numerical pain rating
scale (NPRS) ranged from 5 to 9, which characterizes
moderate to severe pain and may pose problems in
measuring ROM. However, the very good to excellent
reliability proves otherwise, i.e. measurements were still
reliable in patients with moderate to severe painful stiff
shoulders corresponding to stage II. The pre-treatment
value for pain and function indicated moderate to se-
vere problems (SPADI values varied from 42 to 98, on
average 63). The recruited patients had restricted
shoulder movement with more than 30% reduction in
two of three PROM values and none of the three move-
ments were normal. We chose to only examine passive
ABD, ER, IR and HBB as these are the standard move-
ments for diagnosis of shoulder capsulitis and may also
be used over time to monitor progression [34,35]. Since
pain and stiffness pose particular problems while
measuring PROM, for example in finding out the
exact end point of movement, measurement of AROM
could have been a good supplement. Studies have
shown that AROM is more reliable than PROM, prob-
ably because the extra pressure from the examiner
while measuring PROM may affect the ROM [36,37].
The strength of this study lies in its good power, repre-
sentativeness of the condition studied and good to excel-
lent results, as well as being the first study that
measures intertester reliability in patients with shoulder
adhesive capsulitis with plurimeter. Among limitations it
may be mentioned that non-randomization of testers
may have induced systematic measurement error, as
tester 2 may have provoked pain and thus affected the
PROM for tester 1. The testers had two criteria, pain
and stiffness, for judging the end of movement and this
may also have constituted some source of measurement
variation, although small. Despite the non-randomised
test-procedure our results are very good.
Table 5 Mean range and standard deviation (SD) for two testers for hand behind back (HBB) in 50 patients with
shoulder capsulitis
Visit Tests ROM Tester 1 ROM Tester 2 ICC sw
ROM (SD) ROM (SD) 2,1 cm
1. HBB non-affected (cm) 18.3 (5.7) 18.4 (5.8) 0.97 2.1
HBB affected (cm) 0.2 (6.9) 1.5 (7.0) 0.91 1.9
2. HBB non-affected (cm) 19.0 (5.8) 19.0 (5.5) 0.98 0.9
HBB affected (cm) 4.9 (7.3) 4.3 (7.9) 0.94 1.8
3. HBB non-affected (cm) 19.1 (5.0) 19.4 (5.3) 0.96 1.1
HBB affected (cm) 7.9 (8.6) 8.7 (7.9) 0.96 1.6
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Although tester 2, who always tested before tester 1, had
a tendency to measure a larger range for external and in-
ternal rotation, and mostly for the non-affected arm, find-
ings in our study show an overall very good to excellent
reliability for measuring PROM in patients with this con-
dition. This is an important finding because measuring
PROM is the diagnostic test for adhesive shoulder capsuli-
tis. Little difference in intertester reliability occurred for
the duration of the study (eight weeks). Although an intra-
tester reliability study with short time intervals was not
performed, our results indicate that we can trust the mea-
surements from one tester at different visits also in an ef-
fect study.
Conclusion
Intertester reliability between two testers was very good
at three visits over a time period of eight weeks using
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Abduction non-affected side visit 1
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b
Figure 2 Bland-Altman plot with mean abduction values for a) affected and b) non-affected arm in 50 patients with adhesive capsulitis
at visit 1 for both testers plotted against the difference between testers. For the non-affected arm equal values are dispersed by a factor of
0.1 degrees at 90 degrees.
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patients with adhesive shoulder capsulitis. This method
can reliably determine passive range of motion in this
patient population and be a reliable outcome measure.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors contributed to the design of the study. SS recruited the patients,
measured range of motion and drafted the manuscript, performed statistical
analysis with help from AK. AK and AB helped in drafting the manuscript. All
authors have read and approved the final manuscript.
Acknowledgements
Sincere thanks to Nils Ivar Aanes for being the blinded tester. This study was
supported by the General Practice Research Fund of The Norwegian Medical
Association. A grant was also received from Dr. Trygve Gythfeldt and wife’s
research fund.
Author details
1Department of Global Public Health and Primary Care, Research Group for
General Practice, University of Bergen, Bergen, Norway. 2Department of
Global Public Health and Primary Care, Physiotherapy Research Group,
University of Bergen, Bergen, Norway.
Received: 2 December 2014 Accepted: 10 February 2015
References
1. Muir SW, Corea CL, Beaupre L. Evaluating change in clinical status: reliability
and measures of agreement for the assessment of gleno-humeral range of
motion. N Am J Sports Phys Ther. 2010;5:98–110.
2. van der Windt DA, van der Heijden GJ, Scholten RJ, Koes BW, Bouter LM.
The efficacy of non-steroidal anti-inflammatory drugs (NSAIDS) for shoulder
complaints. A systematic review. J Clin Epidemiol. 1995;48:691–704.
3. Green S, Buchbinder R, Glazier R, Forbes A. Interventions for shoulder pain.
Cochrane Database of Syst Rev. 1999, Issue 2. Art. No.: CD001156. doi:
10.1002/14651858.CD001156.
4. van der Heijden GJ, van der Windt DA, Kleijnen J, Koes BW, Bouter LM.
Steroid injections for shoulder disorders: a systematic review of randomized
clinical trials. Br J Gen Pract. 1996;46:309–16.
5. Pal B, Anderson J, Dick WC, Griffiths ID. Limitation of joint mobility and
shoulder capsulitis in insulin- and non-insulin-dependent diabetes mellitus.
Br J Rheumatol. 1986;25:147–51.
6. Hannafin JA, Chiaia TA. Adhesive capsulitis. A treatment approach. Clin
Orthop Relat Res. 2000;372:95–109.
7. Bunker TD, Anthony PP. The pathology of frozen shoulder. A Dupuytren-like
disease. J Bone Joint Surg Br. 1995;77:677–83.
8. Riddle DL, Rothstein JM, Lamb RL. Goniometric reliability in a clinical setting:
shoulder measurements. Phys Ther. 1987;67:668–73.
9. MacDermid JC, Chesworth BM, Patterson S, Roth JH. Intratester and
intertester reliability of goniometric measurement of passive lateral shoulder
rotation. J Hand Ther. 1999;12:187–92.
10. Hayes K, Walton JR, Szomor ZR, Murrell GA. Reliability of five methods for
assessing shoulder range of motion. Aust J Physiother. 2001;47:289–94.
11. Kolber MJ, Vega F, Widmayer K, Cheng MS. The reliability and minimal
detectable change of shoulder mobility measurements using a digital
inclinometer. Physiother Theory Pract. 2011;27:176–84.
12. Nadeau S, Kovacs S, Gravel D, Piotte F, Moffet H, Gagnon D, et al. Active
movement measurements of the shoulder girdle in healthy subjects with
goniometer and tape measure techniques: a study on reliability and validity.
Physiother Theory Pract. 2007;23:179–87.
13. Mullaney MJ, McHugh MP, Johnson CP, Tyler TF. Reliability of shoulder
range of motion comparing a goniometer to a digital level. Physiother
Theory Pract. 2010;26:327–33.
14. Sabari JS, Maltzev I, Lubarsky D, Liszkay E, Homel P. Goniometric assessment
of shoulder range of motion: comparison of testing in supine and sitting
positions. Arch Phys Med Rehabil. 1998;79:647–51.
15. Tveita EK, Ekeberg OM, Juel NG, Bautz-Holter E. Range of shoulder motion
in patients with adhesive capsulitis; intra-tester reproducibility is acceptable
for group comparisons. BMC Musculoskelet Disord. 2008;9:49.
16. Green S, Buchbinder R, Forbes A, Bellamy N. A standardized protocol for
measurement of range of movement of the shoulder using the
Plurimeter-V inclinometer and assessment of its intrarater and interrater
reliability. Arthritis Care Res. 1998;11:43–52.
17. de Winter AF, Heemskerk MA, Terwee CB, Jans MP, Deville W, van
Schaardenburg DJ, et al. Inter-observer reproducibility of measurements of
range of motion in patients with shoulder pain using a digital inclinometer.
BMC Musculoskelet Disord. 2004;5:18.
18. de Vet HCW, Terwee CB, Mokkink LB, Knol DL. Measurements in Medicine.
Cambridge, U.K: Cambridge University Press; 2011. p. 126–8.
19. Pandya S, Florence JM, King WM, Robison JD, Oxman M, Province MA.
Reliability of goniometric measurements in patients with duchenne
muscular dystrophy. Phys Ther. 1985;65:1339–42.
20. Terwee CB, de Winter AF, Scholten RJ, Jans MP, Devillé W, van Schaardenburg
D, et al. Interobserver reproducibility of the visual estimation of range of
motion of the shoulder. Arch Phys Med Rehabil. 2005;86:1356–61.
21. Croft P, Pope D, Boswell R, Rigby A, Silman A. Observer variability in
measuring elevation and external rotation of the shoulder. Primary Care
Rheumatology Society Shoulder Study Group. Br J Rheumatol.
1994;33:942–6.
22. Hoving JL, Buchbinder R, Green S, Forbes A, Bellamy N, Brand C, et al. How
reliably do rheumatologists measure shoulder movement? Ann Rheum Dis.
2002;61:612–6.
23. Awan R, Smith J, Boon AJ. Measuring shoulder internal rotation range of
motion: a comparison of 3 techniques. Arch Phys Med Rehabil.
2002;83:1229–34.
24. de Jong LD, Dijkstra PU, Stewart RE, Postema K. Repeated measurements of
arm joint passive range of motion after stroke: interobserver reliability and
sources of variation. Phys Ther. 2012;92:1027–35.
25. Dias R, Cutts S, Massoud S. Frozen shoulder. BMJ. 2005;331:1453–6.
26. Nagy MT, Macfarlane RJ, Khan Y, Waseem M. The frozen shoulder: myths
and realities. Open Orthop J. 2013;7:352–5.
27. Watson L, Balster SM, Finch C, Dalziel R. Measurement of scapula upward
rotation: a reliable clinical procedure. Br J Sports Med. 2005;39:599–603.
28. Ginn KA, Cohen ML, Herbert RD. Does hand-behind-back range of motion
accurately reflect shoulder internal rotation? J Shoulder Elbow Surg.
2006;15:311–4.
29. Wakabayashi I, Itoi E, Minagawa H, Kobayashi M, Seki N, Shimada Y, et al.
Does reaching the back reflect the actual internal rotation of the shoulder?
J Shoulder Elbow Surg. 2006;15:306–10.
30. Eliasziw M, Young SL, Woodbury MG, Fryday-Field K. Statistical methodology
for the concurrent assessment of interrater and intrarater reliability: using
goniometric measurements as an example. Phys Ther. 1994;74:777–88.
31. Bland JM, Altman DG. Measurement error. BMJ. 1996;312:1654.
32. Stokes EK. Rehabilitation outcome measures. 1st ed. Edinburgh; New York:
Churchill Livingstone; 2011. p. 27–32.
33. Musselman K. Clinical significance testing in rehabilitation research: what,
why, and how? Phys Ther Rev. 2007;12:287–96.
34. Ombregt L, Bisschop P, Veer HJ, Van de Velde T. A System of orthopaedic
medicine. London: Saunders; 1995.
35. Shaffer B, Tibone JE, Kerlan RK. Frozen shoulder. A long-term follow-up.
J Bone Joint Surg Am. 1992;74:738–46.
36. Gajdosik RL, Bohannon RW. Clinical measurement of range of motion:
review of goniometry emphasizing reliability and validity. Phys Ther.
1987;67:1867–72.
37. Fish DR, Wingate L. Sources of goniometric error at the elbow. Phys Ther.
1985;65:1666–70.



























RESEARCH ARTICLE Open Access
Adhesive capsulitis of the shoulder,
treatment with corticosteroid,
corticosteroid with distension or
treatment-as-usual; a randomised
controlled trial in primary care
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Abstract
Background: Optimal management for adhesive shoulder capsulitis (frozen shoulder) is currently unclear. We intended
to explore whether treatment by intra-articular injections with corticosteroid and distension is more effective than
treating with corticosteroids alone or treatment-as-usual in a primary care setting in Norway.
Methods: In this prospective randomised intention to treat parallel study, 106 patients were block randomised to three
groups; 36 (analysed 35) receiving steroid injection and Lidocaine (IS), 34 receiving steroid and additional saline
as distension (ISD) and 36 had treatment-as-usual (TAU). Intervention groups received four injections within 8 weeks,
assessed on 1st visit, at the 4th and 8th week. Outcomes were Shoulder Pain and Disability Index (SPADI), Numerical
pain rating scale (NPRS) and passive range of motion (PROM). Postal assessment was repeated after 1 year for SPADI.
Patients in the IS and ISD groups were “blinded” for intervention received and the assessor was “blinded” to group
allocation.
Results: At baseline there were no differences between groups in outcome measures. There were no statistical
significant differences between the intervention groups in SPADI, NPRS and PROM at baseline, at short-term
(4-and 8 weeks) or long-term (12 months). There were statistically significant differences (p < 0.01) in change
scores at short-term for SPADI when comparing the IS and TAU groups (-20.8; CI-28.9 to -12.7), and the ISD and
TAU groups (-21.7; CI-29.4 to -14.0), respectively for NPRS (-2.0; CI-2.8 to -1.1 and -2.2; CI-3.0 to -1.4), and for PROM,
but not at long-term for SPADI (p > 0.05).
Effect size (ES) at 8 weeks was large between both injection groups and TAU (ES 1.2). At 12 months ES was
reduced to 0.3 and 0.4 respectively. Transitory side effects as flushing and after-pain were reported by 14 % in
intervention groups.
Conclusion: This intention to treat RCT in primary care indicates that four injections with corticosteroid with or
without distension, given with increasing intervals during 8 weeks, were better than treatment-as-usual in treatment of
adhesive shoulder capsulitis. However, in the long run no difference was found between any of the groups, indicating
that natural healing takes place independent of treatment or not.
Trial registration: ClinicalTrials.gov, https://clinicaltrials.gov/ identifier: NCT01570985
Keywords: Adhesive capsulitis, Corticosteroid, Distension, Frozen shoulder
* Correspondence: satya.sharma@uib.no
1Research Group, Section for General Practice, Department of Global Health
and Primary Care, University of Bergen, Kalfarveien 31, N-5018 Bergen,
Norway
Full list of author information is available at the end of the article
© 2016 Sharma et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Sharma et al. BMC Musculoskeletal Disorders  (2016) 17:232 
DOI 10.1186/s12891-016-1081-0
Background
Adhesive capsulitis of the shoulder, also called frozen shoul-
der, has a prevalence of 2 to 5 % of the general population,
but among diabetic patients the prevalence ranged from 11
to 30 % [1, 2]. There is a strong correlation between adhe-
sive capsulitis and other medical conditions such as dia-
betes, rheumatic disease, heart disease, hyperthyreosis [3].
Adhesive capsulitis occurs mostly in middle age [4–6] and
women between 50 and 60 years are most commonly
affected [7]. Both shoulders can be affected simultan-
eously and/or the other side can be affected a few years
later [7, 8]. Shoulder stiffness and pain interferes con-
siderably with activities of daily living, and may be asso-
ciated with increased sick leave in people of working
age and incapacity in the elderly.
Adhesive capsulitis is a long-lasting disorder with spon-
taneous onset of pain and progressive stiffness [9]. It gener-
ally involves reduced movement of the gleno-humeral joint
in several planes, with most restriction of external rotation,
some restriction of abduction and least affection of internal
rotation carried out passively, also called the capsular
pattern [5, 6]. Adhesive capsulitis is primarily a clinical
diagnosis and radiography can be complementary in the
diagnosis [10, 11]. Pathophysiologically, thickening and
contracture of the inferior capsule [12], contracture of the
rotator interval, coraco-humeral ligament and anterior cap-
sule with a combination of synovial inflammation and cap-
sular fibrosis, has been described [10]. Bunker et al. found
the histo-pathological picture comparable to Dupuytren’s
disease of the hand with no inflammation and no synovial
involvement [13]. The natural history remains contro-
versial. Earlier studies considered the condition as self-
limiting, lasting for 2 to 3 years, reporting that the
majority of patients would get almost complete recov-
ery or full recovery [14, 15]. Other authors report long-
term pain and stiffness for several years [16–18]. For
convenience, the condition is divided into three phases;
the painful phase lasting from 3 to 9 months, followed
by a freezing phase with progressive stiffness lasting
from 4 to 12 months and finally, the recovery phase
with gradual return of movement, lasting 5–26 months
[19, 20]. Some have divided the condition into four
stages, based on the correlation of findings on physical
examination and arthroscopic examination [21].
Commonly used conservative therapies for adhesive
capsulitis include non-steroidal anti-inflammatory drugs,
intra-articular glucocorticosteroid injections, oral gluco-
corticosteroid medication, physical therapy, manipulation
under anaesthesia and hydrodilatation [22]. However, des-
pite the amount of research in the topic, results still ap-
pear to be inconclusive regarding effectiveness of the
different treatment modalities [23, 24]. In hydrodilatation
or arthrographic distension procedures, an intra-articular
injection is performed under fluoroscopy with local
anaesthetics, normal saline and often with contrast
medium. Most of the interventional studies with cortico-
steroid injections, with or without hydrodilatation (disten-
sion), have been done with single corticosteroid injection
under fluoroscopy or ultrasound guided, either sub-
acromial or intra-articular or both. Van der Windt et al.
[25] used up to a maximum of three intra-articular injec-
tions over 6 weeks. According to Cyriax’s treatment
method [1], adhesive capsulitis is often treated with be-
tween three to six corticosteroid intra-articular injections
with increasing interval between injections, which is also
supported by others [4–6, 26]. A short term efficacy of
arthrographic distension with normal saline and cor-
ticosteroid versus placebo was demonstrated in a ran-
domised controlled trial (RCT) in patients with painful
stiff shoulder [27]. A systematic Cochrane review regarding
efficacy of hydrodilatation concludes: “there is “silver” level
evidence that arthrographic distension with saline and ster-
oid provides short-term benefits in pain, range of move-
ment and function in adhesive capsulitis. It is uncertain
whether this is better than alternative interventions” [28].
Hydrodilatation studies [29–31] did not demonstrate any
statistically significant differences in functional outcome
compared to steroid injection [32].
The present study has followed the existing practice of
treating patients with adhesive capsulitis in primary care
in Norway. In a pilot trial, there was no clinically signifi-
cant difference in overall results between corticosteroid
alone and corticosteroid with distension [33]. The aim of
this study was to elucidate the effect, if any, of multiple
corticosteroid injections with distension as compared to
multiple corticosteroid injections alone, to treatment-as-
usual.
Methods
This RCT comprises two parallel intervention groups
and a control group allocating equal number of patients.
The intervention period lasted 8 weeks, with a postal
follow-up after 1 year. The patients were recruited from
the city of Bergen and neighboring municipalities by re-
ferral from primary care (PC) practitioners from January
2010 to October 2013.
Included patients had to be above 18 years of age, should
be able to understand and speak Norwegian, and have no
contraindication for use of corticosteroids. Patients should
have reduced passive range of motion (PROM) with a
reduction of more than 30 % of two of three shoulder
movements and none of the three movements (Abduction
=ABD, External rotation = ER and Internal rotation = IR)
should be normal. Patients with diabetes, asthma, preg-
nant women and breast feeding mothers were excluded
from the study. Female patients in fertile age were asked
about prevention.
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Eligible patients were invited to participate in the
study were randomly assigned to one of three groups ac-
cording to serial no. on the closed envelope by one of
authors (SPS). The block randomisation, using a block
size of three, was carried out by one of the supervisors
(AB). Possible permutations were strung together using
a random cipher table. The resulting information on
treatment was printed out and put in a closed envelope
with the patient serial number outside. The envelope
was to be opened after the inclusion of the patient.
Treatment allocation was thereby “blinded” for both re-
searcher and patient at the point of inclusion. The pa-
tients in the active intervention groups were not
informed which treatment option (with or without dis-
tension) was carried out.
Intervention
Intra-articular injections were administered by land-
marks using posterior approach thus preventing the pa-
tients from seeing the size of syringe used. This was to
avoid possible bias as the patients might consider treat-
ment with distension and corticosteroid to be superior
to corticosteroid alone. The injections were administered
by one of the authors (SPS) who is both a general practi-
tioner and a physiotherapist at a primary care center in
municipality of Bergen and has several years of experi-
ence in treating adhesive capsulitis by intra-articular in-
jections both by landmarks and ultrasound guided.
Patients in the steroid alone group (IS) received Tri-
amcinolone 20 mg injection, with Lidocaine 10 mg/ml
3 ml and a total of 4 ml solution. Those in the distension
group (ISD) also received steroid and Lidocaine (Triam-
cinolone 20 mg, 3 ml Lidocaine), but with additional
physiological Sodium chloride 9 mg/ml, comprising a
total volume from 8 ml and upwards to 20 ml. Limiting
factors for injected volume were difficulty in further in-
jection and/or increasing pain during injection. Injection
to IS and ISD groups were given after inclusion on day
1, after 7, 17, and 31 days from the start. Adherence to
planned intervention was assessed continuously by one
of the authors (SPS). Patients receiving treatment-as-
usual (TAU) were informed about the possibilities of
optional conservative treatment, such as physiotherapy
or pain medication other than corticosteroid injections
or per oral corticosteroid medication until 61 days after
inclusion.
Outcome measures
The primary outcome was the Shoulder pain and disabil-
ity index (SPADI), which measures a combination of
pain and functional disability on a score from 0 to 100, a
high score indicating more pain and disability [34]. The
second outcome measure was pain intensity on average
for the previous 7 days, measured on a 10-point
Numerical pain rating scale (NPRS), where 0 meant no
pain and 10 meant unbearable pain. PROM was mea-
sured in sideways elevation (abduction), internal rotation
(by “Hand behind back” method) and external rotation. A
plurimeter, found to be a reliable gravity inclinometer, was
used as the measuring instrument for PROM [35–37].
PROM was measured, also on the normal side, on all
visits. PROM was measured in supine lying position for
external and internal rotation, and for abduction in stand-
ing. The endpoint was when the arm could not be moved
more or the pain became unbearable. To avoid discrepan-
cies in measurements due to affection of movements of
thumb joints, the distance in Hand-behind-back was mea-
sured in centimeters between the styloid process of the ra-
dius to the posterior inferior iliac spine. PROM was
measured by a research collaborator (a GP) being unaware
which group the patients were randomised to. The asses-
sor who took PROM had experience in use of the pluri-
meter, and had shown acceptable inter-tester reliability
[37]. The assessor made entries of the PROM on a separ-
ate paper so that confidentiality was maintained from the
treating doctor throughout the study.
The time intervals between the consecutive treatments
were 1, 1½ and 2 weeks. The control group remained
without treatment with corticosteroids in injection or tab-
let form until 61 days, but could use NSAIDs, Paracetamol
or Codeine as needed. SPADI and NPRS were registered
on the first visit, after 4 and 8 weeks. The 1 year follow-up
for SPADI was only by postal communication.
Sample size
For SPADI, being the primary outcome measure, we con-
sidered an outcome of 20 % better or worse to be clinically
significant. This represents a difference in score of 14 at
the level of SPADI = 70. Others have considered a differ-
ence in score of ≥10 to represent clinically important
change [34, 38]. In a previous study where SPADI was a
primary outcome measure, the variance in SPADI was
19.8 [27]. Given α = 0.05, we calculated the sample size to
be 31 in each group to have an 80 % power to detect a dif-
ference in mean SPADI score of ≥14. With a 10 % drop
out the number of patients required for the study to have
the above mentioned power were calculated to be 34 in
each group.
Statistical analysis
Differences in outcome between the groups were analyzed
using repeated measure ANCOVA and regression based
ANCOVA. In our analysis we have distinguished between
short-term follow-up (4 and 8 weeks) and long-term
follow-up (12 months). Since the 4 and 8 weeks data were
not independent, we chose to analyze these data as mul-
tiple follow-up observations. This was done in a repeated
measures ANCOVA model with 4 and 8 weeks
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observations as repeated measures to capture the main ef-
fect of treatment between groups [39] (p.197), and with
pretest as a covariate to adjust for baseline differences be-
tween subjects. Similarly, we analyzed the long-term
follow-up data in another ANCOVA model using a regres-
sion procedure with the 12 months observations as
dependent variable, group as a categorical independent
variable and pretest as a covariate. In an additional/sec-
ondary analysis we added other independent variables
(specified) to both ANCOVA models to control for pos-
sible confounding.
Effect size (ES) for mean change in SPADI was also
calculated by subtracting post-test score (8 weeks and
12 months) from baseline in two groups, dividing it by
the standard deviation (SD) of the change score:
Effect size ¼ Mean of intervention group½ − Mean of treatment−as−usual group½ 
Standard Deviation
An ES of 0.8 is considered large and of crucial prac-
tical or clinical importance, while an ES of 0.2 is consid-
ered to be small and without any practical or clinical
importance [39].
We performed intention to treat (ITT) analysis [40],
keeping patients in their original allocations on random-
isation in accordance with ITT principles [41]. We had
intervention data for all patients until 8 weeks except for
missing data for two patients for 4 weeks and one pa-
tient for 8 weeks. One year follow-up data was lacking
for six patients. Missing data were imputed following
ITT principles.
Software package IBM SPSS Statistics 22 for Windows,
was used for all statistical analyses.
We have followed the CONSORT (Consolidated Stan-
dards of Reporting Trials) 2010 guidelines for reporting of
parallel group randomised trials. Figure 1 included in the
manuscript has followed 2010 CONSORT Flow Diagram
template. CONSORT 2010 Checklists for Randomised
Trials, CONSORT extension for Abstracts Checklist and
TIDieR (Template for Intervention Description and Repli-
cation) checklist files.
Results
Of the 216 patients referred for the study, 146 met the
inclusion criteria, whereof 40 patients declined to par-
ticipate for fear of coming in the TAU group and not re-
ceiving treatment immediately. Seventy patients were
excluded as they were less affected than the specified
criteria for reduced ROM or had diabetes. One hundred
and six patients were randomised for participation.
Thirty-six patients were allocated to the IS group, 34 pa-
tients to the ISD group, and 36 patients to TAU (Fig. 1).
All completed the specified intervention until 8 weeks,
and there were no dropouts, except for one in the IS
group. After 1 year 100 patients (95 %) answered the
postal questionnaire. One year follow up ended in
December 2014. No interim analysis was carried out
during the trial.
Patient characteristics
Baseline characteristics of all the included patients are
displayed in Table 1. The three groups were comparable
in their baseline regarding age, gender, mean duration of
shoulder pain, concurrent neck pain, previously frozen
shoulder, number of affected right side and dominant
side and sick leaves. There were no statistically signifi-
cant differences between the three groups regarding side
affected, operated shoulder prior to adhesive capsulitis,
trauma to shoulder (traumatic adhesive capsulitis), pre-
vious shoulder treatment, and smoking. There was a sta-
tistically significant difference in use of analgesics at
baseline between the two intervention groups (p < 0.05),
but not between the injection groups and TAU. Further-
more, 11 patients in the distension group had “trauma
to shoulder” whereas the IS group had two and the TAU
had three patients with previous trauma.
Intervention
Thirty-five patients in the IS group and 34 patients in
the ISD group received four injections each within the
time frame of 8 weeks. After the intervention period of
8 weeks, 12 patients (33 %) in the TAU group received
additional treatment with intra-articular injections with
corticosteroid and Lidocaine, same as in the IS group,
for pain relief, and three were operated. During the
8 weeks after recruitment, 11 patients in the TAU group
had received NSAIDs and/or pain killers as needed, and
three patients had received acupuncture for pain relief.
All three groups showed clinically significant change in
SPADI from baseline to 8 weeks (>14 points improve-
ment), although both intervention groups had improved
significantly more as compared to the TAU group at
8 weeks. Similarly, there was a significant improvement in
NPRS at 8 weeks for both intervention groups, but less in
the TAU group. Change in PROM for abduction was
slightly better between the distension group (54° increased
to 69°; i.e. 15° increase) and the TAU group (51° increased
to 57°; i.e. 6° increase) at 8 weeks (Table 2).
Both intervention groups had equivalent ES concern-
ing SPADI at 8 weeks (ES 1.2) and 12 months (ES 0.3
and 0.4) (Table 3). At 12 months, however, the change in
the TAU group was as large as the change in the two
intervention groups and no statistical significant differ-
ence was found in SPADI between the three groups,
illustrated in Fig. 2.
Repeated measure ANCOVA for short-term and re-
gression based ANCOVA for long-term revealed no
statistically significant difference between the two inter-
vention groups in SPADI, NPRS and PROM, neither at
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baseline, nor at short-term, or in SPADI at long-term. A
statistically significant change (p <0.001) was found for
both intervention groups when compared to the TAU
group at short-term for SPADI and NPRS. There was a
statistically significant difference (p < 0.01) at short-term
for all PROMs between the two injection groups and TAU
(Table 4).
In the TAU group, three patients were operated after
8 weeks, and 12 patients chose to receive intra-articular
corticosteroid injections without distension. In the
intention-to-treat analysis at 12 months, including all
patients in the groups to which they were allocated,
there were no significant differences between any of the
groups regarding change in SPADI (Table 4).
In our study there was only one drop out up to 8 weeks
and we did not expect this to affect the results substantially.
A secondary per-protocol analysis was performed excluding
the 15 patients that did not follow the initial TAU protocol
after the 8 week period. This did not affect the results.
However, we do acknowledge the fact that exclusion of
these patients lowers the sample power for the TAU group.
Five patients (14 %) in the IS group, eight patients
(24 %) in ISD group and six patients (14 %) in the TAU
group were still on sick leave after 1 year. Eight patients
Fig. 1 Flow diagram for randomisation and follow-up
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(22 %) in the IS group, nine patients (26 %) in the ISD
group and three patients (8 %) in the TAU group were
still on medication for shoulder pain at 12 months
follow-up.
Six patients (17 %) in the IS group and four (12 %) pa-
tients in the ISD group experienced minor transitory side-
effects such as flushing and after-pain. No incidences of
other side effects were reported. Patients in the two injec-
tion groups were asked to guess to which group they
belonged to after the last injection. Twenty-six patients
(38 %) guessed the wrong group.
Discussion
Repeated intra-articular steroid injections given with in-
creasing intervals in the gleno-humeral joint gives short-
term (8 weeks) benefit. Added capsular distension did
not significantly affect the outcome measures for SPADI,
NPRS and PROM. However, at long-term follow-up,
those who had received no intervention did equally well.
Earlier studies combining distension (10 ml) and cortico-
steroid versus distension alone and corticosteroid alone,
have reported better results for distension [42]. While in
studies by Corbeil et al. & Tveitå et al. [30, 31] no signifi-
cant differences between distension and non–distension
arthrography with corticosteroids were found, the main ef-
fect might therefore be attributed to corticosteroid alone.
Comparing our results between ISD group and TAU group
with Tveitå et al. [31], our study has demonstrated larger
improvement; for SPADI 24 versus 6, for ABD 15.4 versus
2, for ER 18.7 versus 2 and for IR 12.3 versus 3 respect-
ively. A systematic review concluded with “silver level”
evidence for short–term efficacy in pain, ROM, and
function of shoulder by arthrographic saline distension
and corticosteroid in patients with adhesive capsulitis
[28]. Studies with distension and corticosteroid causing
capsular rupture performed in hospital settings have also
shown significant results [27, 29, 42]. These and other case
series studies in primary care with distension and capsular
rupture [43, 44] are, however, not comparable to the
present study, as capsular rupture was not the intended
intervention. We cannot however rule out that capsular
rupture might have occurred in some patients. Tveitå et
al. [31] have observed capsular rupture at a volume as low
as 10 ml.
A dose of 20 mg Triamcinolone was a tradeoff dose be-
tween effect and side effects in both intervention groups
and is the generally accepted and practiced treatment dose
for adhesive capsulitis in primary care. A study by de Jong
[45] has shown better effect with a dose of 40 mg Triam-
cinolone than with 10 mg, whereas another study by Yoon
et al. [46] found no significant difference in outcome be-
tween a dose of 20 and 40 mg Triamcinolone. In this
study we used a series of injections, a total of four over a
period of 8 weeks. Many studies with distension have only
used a single corticosteroid injection, which makes com-
parison difficult. Only a few studies have used multiple in-
jections and even fewer have used multiple injections with
dilatation [25, 29, 31, 42, 47]. A review has concluded that
multiple injections improve pain and ROM in short term
from 6 to 16 weeks from the first injection. There is evi-
dence that up to three injections can be beneficial and
limited evidence that up to six injections is beneficial [4].
This study has followed the actual practice of treating
these patients in primary care with intra-articular injec-
tions by landmarks, without fluoroscopic guidance. Some
studies with ultrasound guided intra-articular steroid
Table 1 Baseline characteristics of patients
Characteristics Injection group Steroid alone (IS) Injection group Steroid and saline (ISD) Treatment-as-usual (TAU) group
Number and % within group
n = 36
Number and % within group
n = 34
Number and % within group
n = 36
Mean age (years) 52 (8.3) 53 (9.2) 54 (6.9)
Female 21 (58 %) 21 (62 %) 19 (53 %)
Duration in months Median (range) 7.5 (2.0–18.0) 7.0 (3.0–37.0) 6.0 (3.0–24.0)
Affected right shoulder 18 (50 %) 12 (35 %) 15 (42 %)
Previous frozen shoulder 6 (17 %) 4 (11 %) 4 (11 %)
Concurrent neck pain 16 (44 %) 15 (44 %) 16 (44 %)
Trauma to shoulder 2 (6 %) 11 (32 %) 3 (8 %)
Previous operation on shoulder 3 (8 %) 3 (9 %) 1 (3 %)
Dominant right side 34 (94 %) 30 (88 %) 34 (94 %)
Previous shoulder treatment 15 (42 %) 22 (65 %) 13 (36 %)
Analgesics 19 (53 %) 14 (41 %) 11 (31 %)
Participants on sick leave 17 (50 %) 16 (47 %) 15 (42 %)
Smokers 8 (22 %) 6 (18 %) 12 (33 %)
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injections claim a short time superiority in pain reduction
of about 2 weeks, compared to injections by landmarks
[48], which we consider is little as compared to the extra
resources required in terms of time and costs.
On 1 year follow-up all three groups had similar out-
come, which reflects the natural history of the condition
[14, 16, 18, 20, 49]. But the major difference in pain
relief (NPRS) and pain and function (SPADI) were re-
corded in the first 8 weeks in the intervention groups as
compared to the control group. From the patient’s per-
spective, pain relief leading to undisturbed sleep is of
great importance [50], which is not so often accredited
in studies measuring outcome over time.
One of the strengths of this study is that it is con-
ducted in line with the actual practice in treatment of
Table 3 Effect size (ES) for SPADI from baseline to 8 weeks and
12 months follow-up for the three groups
SPADI IS ISD TAU IS & ISD IS & TAU ISD & TAU
8 weeks
Mean change −40.3 −40.4 −17.4 0.2 22.8 23.0
SD 19.0 19.1 19.8 19.1 19.4 19.4
ES 0.0 1.2 1.2
12 months
Mean change −43.0 −39.8 −48.1 3.1 5.1 8.2
SD 19.6 24.7 20.4 22.3 20.0 21.4
ES 0.1 0.3 0.4
SPADI shoulder pain and disability index
IS injection steroid alone, ISD injection steroid plus saline, TAU treatment-as-usual
Table 2 SPADI, NPRS and PROM and comparison in outcomes between three groups
Injection group Steroid alone (IS) Injection group Steroid and saline (ISD) Treatment-as-usual (TAU)
Mean (SD) Mean (SD) Mean (SD)
Primary outcome variable
SPADI
At inclusion 63.8 (16.0) 60.5 (16.8) 61.9 (19.0)
4 weeks 34.1 (21.4) 30.9 (21.0) 51.9 (22.2)
8 weeks 23.8 (22.0) 20.1 (18.4) 44.4 (23.6)
12 months 16.9 (18.9) 17.2 (19.8) 11.7 (20.3)
Secondary outcome variable
NPRS
At inclusion 6.9 (1.4) 7.2 (1.6) 6.6 (2.1)
4 weeks 3.8 (2.2) 3.5 (1.7) 5.6 (2.5)
8 weeks 3.0 (2.3) 2.9 (1.6) 4.7 (2.0)
Tertiary outcome variables
Abduction (ABD)
At inclusion 53.7 (13.4) 51.0 (17.8) 50.5 (19.0)
4 weeks 62.7 (15.6) 64.7 (17.2) 53.9 (19.4)
8 weeks 68.9 (15.3) 71.9 (17.0) 56.5 (20.9)
External rotation (ER)
At inclusion 19.6 (14.7) 25.2 (17.7) 17.3 (13.5)
4 weeks 30.1 (16.3) 35.6 (15.8) 18.8 (14.8)
8 weeks 38.2 (17.6) 42.7 (17.9) 24.0 (18.1)
Internal rotation (IR)
At inclusion 38.8 (15.5) 41.1 (14.1) 40.2 (15.4)
4 weeks 49.5 (17.4) 52.7 (17.3) 43.7 (16.6)
8 weeks 57.2 (15.7) 59.6 (16.1) 47.3 (18.2)
Hand behind back (HBB)
At inclusion 0.4 (6.2) 2.2 (7.8) −0.5 (6.0)
4 weeks 5.9 (7.2) 7.5 (7.8) 1.0 (6.1)
8 weeks 10.1 (6.3) 11.2 (7.2) 4.3 (6.5)
SPADI shoulder pain and disability index, NPRS numeric pain rating scale, PROM passive range of motion
IS injection steroid alone, ISD injection steroid plus saline, TAU treatment-as-usual
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adhesive shoulder capsulitis in primary care in Norway,
i.e. intra-articular steroid injection in gleno-humeral
joint by landmarks. There are very few studies that are
close to actual practice in treatment of shoulder adhe-
sive capsulitis in primary care [25, 51]. The procedure
is safe and simple and easy to learn and cost
effective. Only 15 % of patients reported transient
side effects and the procedure was not experienced as
particularly painful. The limitations of the study are
lack of visual verification of delivery of medication in
the joint. The injected volume varied from 8 to 20 ml
and we cannot assert with certainty that the observed
Table 4 SPADI, NPRS and PROM: Differences in change scores between the two injection groups (Intervention steroid alone (IS);
Intervention steroid plus saline (ISD)) and the treatment-as-usual group (TAU)
Between groups differences in change, mean (95 % CI)
IS vs ISD IS vs TAU ISD vs TAU
Primary outcome variable
SPADI
Short-term (4 and 8 weeks)a 1.2 (−7.1 to 9.6) −20.8 (−28.9 to −12.7)*** −21.7 (−29.4 to −14.0)***
Long-term (12 months)b 0.1 (−10.4 to 10.7) −7.0 (−16.4 to 2.5) −7.0 (−16.8 to 2.8)
Secondary outcome variable
NPRS
Short-term (4 and 8 weeks)a 0.3 (0.6 to 1.2) −2.0 (−2.8 to −1.1)*** −2.2 (−3.0 to −1.4)***
Tertiary outcome variables
Abduction
Short term (4 and 8 weeks)a −4.5 (−9.7 to 0.8) 8.3 (2.3 to 14.3)** 12.7 (6.6 to 18.9)***
External rotation
Short term (4 and 8 weeks)a −0.9 (−5.8 to 4.1) 10.8 (5.8 to 15.9)*** 11.9 (6.8 to 17)***
Internal rotation
Short term (4 and 8 weeks)a −1.1 (−6.6 to 4.5) 8.8 (3.1 to 14.6)** 9.9 (4.7 to 15.1)***
Hand behind back
Short term (4 and 8 weeks)a −0.7 (−2.4 to 2.2) 5.0 (2.8 to 7.2)*** 5.1 (2.9 to 7.2)***
SPADI shoulder pain and disability index, NPRS numeric pain rating scale, PROM passive range of motion
***p < 0.001, **p < 0.01, *p < 0.05
aRepeated measures ANCOVA with baseline value as covariate. Differences and CIs from estimated marginal means
bRegression based ANCOVA with baseline value as covariate
Fig. 2 Comparison between intervention and treatment-as-usual groups from inclusion to 52 weeks for SPADI
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effect was due to distension and not to capsular rup-
ture. Longer time taken in injecting the fluid in the
joint might have introduced bias as patients might as-
sume that he or she was in the distension group,
which might have been considered the superior method
by the patients.
Conclusion
This intention to treat RCT in primary care indicates that
four injections with corticosteroid with or without disten-
sion, given with increasing intervals during 8 weeks, were
better than treatment-as-usual in adhesive capsulitis of
the shoulder. However, in the long run no difference was
found between any of the groups, indicating that natural
healing takes place independent of treatment.
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Frozen shoulder or capsulitis of the shoulder has a preva-
lence of 2–5% in the general population and occurs mostly
in middle age between 40 and 60 years. Women are more
commonly affected than men [1–4]. Both shoulders can
be affected simultaneously or one side becomes affected
first and then the other side a few years later in 6–17% of
patients [5–7]. One has observed a significantly adverse
impact on pain, function and quality of life in patients
with shoulder adhesive capsulitis as measured with Shoul-
der Pain and Disability Index (SPADI) and the Short Form
survey-36 (SF-36) [8]. The burden of shoulder conditions,
in terms of affecting a patient’s perception of his or her
general health, has been ranked as highly as the burden of
having any of hypertension, congestive heart failure, acute
myocardial infarction, diabetes mellitus and/or depression
[9, 10]. In a systematic review of prognostic factors for
arm, neck and shoulder complaints, the duration and de-
gree of symptoms and resulting limitation of shoulder
function were prognostic for recovery [11]. Another sys-
tematic review found that a high SPADI score [12], in
addition to greater severity and longer duration of shoul-
der pain were associated with becoming the shoulder pain
chronic [13]. Kuijpers et al. had similar findings regarding
the duration and severity of pain at the time of presenta-
tion and its association with chronic shoulder pain [14].
Comorbid factors had a significant effect on pain and dys-
function, as measured on shoulder-specific and general
health instruments, experienced by patients with adhesive
shoulder capsulitis [15]. General health may also be seen
to improve after reduction in shoulder pain and dysfunc-
tion. Functional outcome as measured by SF-36 after
arthroscopic release in refractory adhesive shoulder capsu-
litis, improved clinical and general health status for most
of the patients [16, 17].
Several questionnaires are available to measure com-
plaints among patients with chronic conditions [18]. In
Nordic countries, a validated questionnaire consisting of
29 parameters have been used to measure severity and
duration of subjective somatic and psychological com-
plaints during the previous 30 days. The SHC question-
naire is a systematic, easy and reliable way to measure
subjective health status and comorbidity [19]. It is also ar-
gued, that what may be termed as “medically unexplained
symptoms” or functional somatic syndromes [20], are bet-
ter covered under “subjective health complaints” [21].
Subjective health complaints concerning musculoskeletal
disorders, the digestive system, tiredness, dizziness, sleep
and unspecific pain etc. are common in the general popu-
lation [22, 23]. Prevalence of reported SHC was found
high in general Norwegian population, where 80% re-
ported diverse musculoskeletal complaints e.g. headache,
neck pain, back pain, pain in the arms, shoulder pain, mi-
graine and or pain in the feet on exertion. Whereas 65%
reported “pseudoneurological” complaints, including sleep
problems, tiredness, anxiety, depression, dizziness, hot
flushes and/or extra systoles, among others [23]. The SHC
questionnaire has not been used earlier for measuring
health status in patients with frozen shoulder.
Apart from the clinical characteristics, psychological fac-
tors also play a role in predicting outcome of neck and
shoulder symptoms [24]. The relationship between psycho-
social factors particularly related to work environment and
development of musculoskeletal complaints and the transi-
tion to a chronic state has been hypothesized by some au-
thors and explanatory models are suggested [25, 26].
Further, the physical and psycho-social disability in patients
with chronic pain has been shown to be associated with
patients’ pain-related beliefs [27]. Pain related fear and
avoidance is postulated to be an essential feature of chronifi-
cation of pain for at least some patients [28].
Neuroticism is a broad personality trait that reflects the
extent to which a person experiences the world as stress-
ful, threatening, and problematic. “Neuroticism has been
linked to a wide array of clinical syndromes, with particu-
larly strong associations to distress-based disorders such
as major depression and generalized anxiety disorder. The
trait has also been found to be a significant predictor of
Subjective Health Complaints” [29]. The aspect that
whether patients with frozen shoulder have comorbidity
and have neurotic symptoms that may influence response
to treatment has previously not been studied.
Aim
The aim of this study was to investigate whether Subject-
ive Health Complaints and Neuroticism would predict
treatment outcome in patients diagnosed with frozen
shoulder as measured by SPADI and change in SPADI.
Hypothesis
Comorbidity as measured with SHC and Neuroticism at
baseline can predict outcome in frozen shoulder as mea-
sured by SPADI at 8 weeks and change in SPADI from
baseline to 8 weeks.
Methods
Patients in this study were participants in a randomised
controlled trial (RCT), where 69 were in the intervention
group and received intraarticular corticosteroid injections
during a period of 8 weeks and 36 patients were in the con-
trol group [30]. Most of the patients were in stage II of fro-
zen shoulder with SPADI score around 60. The SPADI was
used as the outcome measure. We measured SPADI at
8 weeks and change in SPADI from baseline to 8 weeks.
We interpret change in SPADI as a measure of rate of re-
covery. There were statistically significant differences be-
tween those receiving intervention and the control group
after 8 weeks in the primary outcome measure. At inclusion
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and after 8 weeks, comorbidity was measured with the
SHC questionnaire and Neuroticism was measured with
the Neuroticism (N) component of the Norwegian version
of the Eysenck Personality Questionnaire- Revised short
form (EPQ-R) [31–33].
SPADI measures a combination of pain and functional
disability on a score ranging from 0 to 100, a high total
score indicating more pain and disability [12]. In the SHC
questionnaire, severity of each complaint is rated on a 4-
point scale (0 = none, 1 = some, 2 = much, 3 = severe). In
this study, we calculated the total SHC scores for 29 items
and differentiated SHC scores in five subscales. These are:
Musculoskeletal (comprising headache, neck pain, back
pain, pain in arms, shoulder pain, migraine and pain in feet
on exertion); Pseudoneurology (sleep problems, tiredness,
anxiety, depression, dizziness, hot flushes and extra sys-
toles); Gastrointestinal (stomach discomfort, heartburn,
ulcer/non-ulcer dyspepsia, stomach pain, flatulence, diar-
rhea and obstipation), Cold/Flu (flu, bad cold, cough/bron-
chitis) and Allergy (asthma, chest pain, breathing difficulty,
eczema and allergy) [19]. The EPQ-R questionnaire has
four scales: E (Extraversion vs. Introversion), N (Neuroti-
cism or Emotionality), P (Psychoticism or Tough Minded-
ness) and L (Lie scale). The short form Neuroticism (N)
questionnaire has 12 questions to be answered with yes or
no options and only this part was used in this study [31].
Statistics
Baseline variables of comorbidity and Neuroticism were ex-
plored. To have an overview of the burden of symptoms,
we performed descriptive analysis of SHC with its subscales
and Neuroticism. To select appropriate baseline scores as
predictors of outcome, we explored correlations between
SPADI at 8 weeks and change in SPADI from baseline to
8 weeks with baseline SHC total and subscale scores, and
with the Neuroticism sum score. Multiple regression ana-
lysis was performed with the items that correlated signifi-
cantly with SPADI at 8 weeks and change in SPADI from
baseline to 8 weeks as predictors, controlling for interven-
tion, age, gender and duration of shoulder pain. We chose
a backward elimination method for multiple regression
analysis, and removed non-significant predictors one by
one. Both initial and final models are reported.
Results
Baseline characteristics of patients and SPADI are displayed
in Tables 1 and 2. There were no noteworthy differences in
the demography between the intervention and control
groups at baseline except for a higher percentage of patients
with trauma in the intervention group. The baseline SPADI
was similar in the two groups (Table 2). Descriptive scores
for SHC and for Neuroticism at baseline and 8 weeks pre-
sented in Table 3, show relatively low prevalence of health
complaints. The preliminary correlation analysis returned
significant Pearson’s correlation coefficients for SPADI at
8 weeks versus total SHC score at baseline, the Pseudo-
neurology subscale in SHC at baseline (p = 0.009), as well
as group allocation (p < 0.001) (Table 4). None of the other
SHC subscales at baseline returned significant correlation
coefficients. There was a significant correlation between fe-
male gender and SPADI at baseline. When we removed the
Pseudoneurology subscale from the total SHC score at
baseline, the remaining total SHC score became insignifi-
cant. This showed that the significant correlation coefficient
related to the total SHC baseline score was due to inclusion
of the Pseudoneurology subscale. Therefore, only the Pseu-
doneurology subscale and not the total SHC baseline score
was kept as predictor in the multiple regression analysis.
No correlation was found between baseline Neuroticism
and the outcome measure after 8 weeks. Correlation ana-
lysis with change in SPADI from baseline to 8 weeks
showed statistically significant correlation to group alloca-
tion and female gender (Table 4).
Table 1 Baseline characteristics of patients diagnosed with
frozen shoulder
Characteristics Intervention group
Number and % within
group n = 69
Control group
Number and % within
group n = 36
Mean age (years) 53 (8.7) 54 (6.9)
Female 42 (60%) 19 (53%)
Duration in months:
Median (range)
7.2 (2.0–37.0) 6.0 (3.0–24.0)
Affected right shoulder 30 (43%) 15 (42%)
Previous frozen shoulder 10 (14%) 4 (11%)
Concurrent neck pain 31 (44%) 16 (44%)
Trauma to shoulder 13 (19%) 3 (8%)
Previous operation on
shoulder
6 (9%) 1 (3%)
Dominant right side 64 (91%) 34 (94%)
Previous shoulder
treatment
37 (53%) 13 (36%)
Analgesics 33 (47%) 11 (31%)
Participants on sick
leave
14 (20%) 15 (42%)
Smokers 6 (18%) 12 (33%)
Table 2 SPADI at baseline and 8 weeks, and change in SPADI








Baseline 62.3 (16.4) 61.4 (19.07)
8 weeks 22.2 (20.3) 43.5 (23.8)
Change from baseline to
8 weeks
40.2 (19.0) 17.8 (15.0)
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Multiple regression analysis with SPADI at 8 weeks as
the dependent variable, controlling for age and gender,
revealed a statistically significant predictive value for
Pseudoneurology in SHC at baseline (p < 0.001) and
group allocation (p < 0.001) (Table 5). Shoulder pain
duration was also registered but did not show any statis-
tically significant predictive value.
Being allocated to the intervention or control group
exhibited statistical significant predictive value. This was
also the case for change in SPADI from baseline to
8 weeks (p < 0.001). Baseline SHC scores did not have
significant predictive value at 8 weeks for a change in
SPADI. Shoulder pain duration showed a statistically sig-
nificant predictive value for change in SPADI from base-
line to 8 weeks (p < 0.01).
Discussion
In this study, we found that patients with frozen shoulder
had little comorbidity as measured with SHC and they
scored normally on the Neuroticism questionnaire. We
found that both the SHC Pseudoneurology subscale and
group allocation predicted pain and function as measured
by SPADI at 8 weeks. However, when looking at factors
predicting change in SPADI from baseline to 8 weeks,
shoulder pain duration and group allocation predicted
better outcome, while SHC as a whole and each subscale
lost its predictive power.
Most of the participants were in stage II of frozen
shoulder [30] with relatively high baseline SPADI score
(Table 2). The mean duration of frozen shoulder at the
time of inclusion in the study was 6 months (Table 1).
Some patients go through a very painful phase and de-
layed diagnosis resulting in frustration, anxiety and de-
pression. Jones et al. observed in their study that lack of
diagnosis or misdiagnosis led to diverse consequences
among the participants; for example, anxiety, denial and
delays in definitive diagnosis and referral [34]. In pa-
tients with cervical radiculopathy, variables regarding
present neck pain intensity, fear avoidance and anxiety
were most significant in dimensions underlying pain and
disability, personal factors and health status [35]. One of
the major complaints in frozen shoulder in late stage I
and stage II is pain which in some cases can be very se-
vere [36], resulting in very disturbed sleep and tiredness.
Perceived disability in patients with chronic shoulder
pain has been found to be strongly influenced by





Baseline 8 weeks Baseline 8 weeks
SHC - Total score 29 items
(score 0–87)
15.34 (8.16) 11.33 (8.04) 12.22 (6.66) 11.08 (7.98)
Musculoskeletal (8 items)
(score 0–24)
8.11 (4.06) 5.62 (3.87) 7.44 (3.45) 6.50 (3.57)
Pseudoneurology (7 items)
(score 0–21)
4.17 (3.03) 3.23 (2.98) 3.11 (2.67) 2.86 (3.07)
Gastrointestinal (7 items)
(score 0–21)
1.70 (2.30) 1.35 (1.92) 0.92 (1.44) 0.94 (1.66)
Flu (2 items)
(score 0–9)
0.57 (1.11) 0.67 (1.07) 0.56 (1.27) 0.53 (1.08)
Allergy (5 items)
(score 0–15)
0.76 (1.36) 0.48 (0.95) 0.25 (0.55) 0.36 (1.05)
Neuroticism
(score 0–12)
2.42 (2.14) 1.57 (2.05) 2.06 (2.28) 1.50 (1.80)
Table 4 Pearson’s correlationsa between independent variables and SPADI at 8 weeks and change in SPADI from baseline to
8 weeks
Correlated independent variables SPADI at 8 weeks Change in SPADI
(baseline to 8 weeks)
Pearson’s r p-value Pearson’s r p-value
SHC Pseudoneurology baseline 0.26* 0.009 0.11 0.287
Gender (male = 0; female = 1) 0.08 0.429 0.26* 0.007
Group allocation (control = 0; intervention = 1) − 0.45* < 0.001 − 0.43* < 0.001
Shoulder pain duration − 0.16 0.108 0.28* 0.004
*p < 0.05
aOnly variables with significant correlations are listed in the table
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depressive symptoms [37]. In our study, 44% of patients
in both groups also had neck pain, which may have con-
tributed to elevated self-experience of pain or disability
(Table 1). It is possible, that after receiving information
at the time of inclusion in the study regarding frozen
shoulder and its natural course patient’s anxiety and de-
pressive symptoms were reduced. The Pseudoneurology
subscale was no longer significantly predictive with re-
gard to change in SPADI from baseline to 8 weeks.
In this study, the follow up was limited to 8 weeks and
this may affect external validity. A further follow up at 6
or 12 months would have been appropriate to predict
long-term outcome. This is a limitation of this study.
Since we lack reference values for SHC and Neuroti-
cism, we cannot compare our findings with the general
population. This is also a limitation of the study.
In our study, Neuroticism did not have any significance in
predicting the outcome of frozen shoulder. Others have
found that personality factors may modulate presentation of
pain and symptoms and influence a broad range of health
outcomes and mechanisms [20, 38]. Rozencwaig et al. have
demonstrated that the number of medical conditions has a
quantitative effect on shoulder function. The parameters for
general health perception and vitality in the SF-36 question-
naire has previously been found to have a strong negative
correlation with the increasing comorbidity in patients with
gleno-humeral degenerative joint disease [39].
Belonging to the intervention group had significant
predictive value (p < 0.001) for both SPADI at 8 weeks
and change in SPADI from baseline to 8 weeks. Con-
trary to what we had expected, SHC total score, SHC
subscales and Neuroticism had no predictive value for
change in SPADI from baseline to 8 weeks. We ex-
pected the Musculoskeletal subscale to have a predict-
ive power because this subscale contains parameters
regarding neck pain, back pain, pain in arms,
shoulder pain and pain in feet, which are relevant to
this study. We do not have any good explanation for
this lack of predictive influence. Absence of predictive
power for Neuroticism is in accordance with findings
in other studies. Ring et al. found that self-reported
upper extremity-specific health status correlated with
the Disabilities of the Arm, Shoulder and Hand
(DASH) questionnaire, but not with Neuroticism, as
measured by the EPQ-R [40]. Factorial analysis of
subjectively felt health complaints by Ursin et al. re-
vealed that factors involving neck, back, arm and
shoulder pain and migraine, did not relate to anxiety
and depression [41]. Psychological factors explained
only a moderate amount of variance of muscle pain,
when the population was looked at as a whole, in
their study [41]. This is similar to our findings, i.e.
the Musculoskeletal subscale did not show predictive
power for SPADI. In general, psychological comorbid-
ity has been found to enhance self-experience of suf-
fering due to pain and dysfunction. Bagheri et al.
reported more suffering due to depression and anxiety
than that from a reduced range of motion in patients
with frozen shoulder [42]. Further, physical and psy-
chosocial disability in patients with chronic pain have
been shown to be associated with patients’ pain-
related beliefs [27]. Patients with psychological disor-
ders have been found to have more self-reported pain
and functional disability in activities of daily life, indi-
cating correlation with frozen shoulder and psycho-
logical conditions [43]. However, the Musculoskeletal
subscale did not predict the outcome in our study
even though it has components of pain parameters.
There is a possibility that the SHC and Neuroticism
questionnaires are not able to measure psychometric
parameters when these are not sufficiently accentu-
ated or are dominating the clinical picture. However,
Table 5 Multiple regression models with backward elimination for participants (n = 105, control and intervention groups) with the
Shoulder Pain and Disability Index (SPADI) at 8 weeks and change in SPADI from baseline to 8 weeks as dependent variables
Initial model Final model
B p-value R2 B p-value R2
SPADI at 8 weeks 0.30 0.29
SHC Pseudoneurology baseline 2.4 0.001 2.6 < 0.001
Gender (male = 0; female = 1) 0.78 0.85
Age − 0.36 0.15
Group allocation (control = 0; intervention = 1) − 25.1 < 0.001 − 24.8 < 0.001
Change in SPADI from baseline to 8 weeks 0.36 0.36
SHC Pseudoneurology baseline 0.19 0.77
Gender (male = 0; female = 1) 11.78 0.002 11.99 0.002
Age 0.48 0.04 0.47 0.04
Group allocation (control = 0; intervention = 1) 19.50 < 0.001 19.73 < 0.001
Shoulder pain duration 0.93 0.91 0.013
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frozen shoulder may be a very distinct physical and
clinical entity, without associated psychological as-
pects. When patients are informed of the diagnosis,
its natural history and possible outcome after inter-
vention, the condition is no longer dramatic and they
cope well with it. According to available literature,
psychometric parameters can in some way affect the
outcome [15, 24–26], but it was not obvious or con-
sistent in our study.
Conclusion
Psychometric parameters as measured by the Pseudo-
neurology subscale in SHC questionnaire did predict the
treatment outcome in frozen shoulder as measured by
SPADI at 8 weeks, but not by change in SPADI from
baseline to 8 weeks. One may conclude that psychomet-
ric parameters may affect symptoms, but do not predict
the rate of recovery in frozen shoulder.
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